

ARNOLD  
WHITE &  
DURKEE

A PROFESSIONAL CORPORATION  
ATTORNEYS AT LAW

Austin  
Chicago  
Houston  
Menlo Park  
Minneapolis  
Washington




Box 509  
750 Bering Drive  
Houston, Texas 77057-2198

Telephone 713.787.1400  
Facsimile 713.787.1440

Writer's Direct Dial:  
(713) 268-1327

January 7, 2000

FILE: MOBT:212



<p>CERTIFICATE OF EXPRESS MAILING</p> <p>NUMBER EL392859935US</p> <p>DATE OF DEPOSIT January 7, 2000</p> <p>I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.</p> <p><i>Ronnie Davis</i> Signature</p>
---

**BOX PATENT APPLICATION**

Assistant Commissioner for Patents  
Washington, DC 20231

RE: *U.S. Patent Application Entitled: "Polyhydroxyalkanoate Biosynthesis Associated Proteins and Coding Region in Bacillus Megaterium" by Maura C. Cannon et al.*

Sir:

Transmitted herewith for filing is a 112-page patent specification including 23 claims and an abstract. Also included are Figures 1-10 on 17 sheets. The specification and drawings constitute the application of The University of Massachusetts for the captioned invention.

Also transmitted herewith is a diskette containing the computer-readable form of those sequences in the specification, a Statement as Required Under 37 C.F.R. § 1.821(f), and a separate paper copy of the sequence listing.

Please note that this application is filed without an inventors' Declaration and Assignment, and a Power of Attorney. Pursuant to 37 C.F.R. § 1.53(b) and (f), the Applicants request the Patent and Trademark Office to accept this application and accord a serial number and filing date as of the date this application is deposited with the U.S. Postal Service for Express Mail. Further, the Applicants request that the NOTICE OF MISSING PARTS-FILING DATE GRANTED pursuant to 37 C.F.R. § 1.53(f) be sent to the undersigned Applicants' representative.

ARNOLD WHITE & DURKEE

Assistant Commissioner for Patents

January 7, 2000

Page 2

Please date stamp and return the enclosed postcard to evidence receipt of this application.

Please forward any reply to this communication directly to our Houston office for docketing purposes. The mailing address and the physical address for courier packages is 750 Bering Drive, Houston, Texas, 77057-2198, and the Houston fax number is 713.787.1440.

Respectfully submitted,



Christopher J. Buntel, Ph.D.

Reg. No. 44,573

eg

Encls.

00406040-010700

Page 3

bcc: E. Bradley Moynahan (w/Encl.)  
Jon H. Beusen, Esq. (w/Encl.)  
Gail Wuellner, Paralegal (w/Encl.)  
Patricia A. Kammerer, Esq. (w/o Encl., via email)

1. **Introduction**  
 2. **Background**  
 3. **Methodology**  
 4. **Results**  
 5. **Discussion**  
 6. **Conclusion**  
 7. **References**  
 8. **Appendix**  
 9. **Figure 1**  
 10. **Figure 2**  
 11. **Figure 3**  
 12. **Figure 4**  
 13. **Figure 5**  
 14. **Figure 6**  
 15. **Figure 7**  
 16. **Figure 8**  
 17. **Figure 9**  
 18. **Figure 10**  
 19. **Figure 11**  
 20. **Figure 12**  
 21. **Figure 13**  
 22. **Figure 14**  
 23. **Figure 15**  
 24. **Figure 16**  
 25. **Figure 17**  
 26. **Figure 18**  
 27. **Figure 19**  
 28. **Figure 20**  
 29. **Figure 21**  
 30. **Figure 22**  
 31. **Figure 23**  
 32. **Figure 24**  
 33. **Figure 25**  
 34. **Figure 26**  
 35. **Figure 27**  
 36. **Figure 28**  
 37. **Figure 29**  
 38. **Figure 30**  
 39. **Figure 31**  
 40. **Figure 32**  
 41. **Figure 33**  
 42. **Figure 34**  
 43. **Figure 35**  
 44. **Figure 36**  
 45. **Figure 37**  
 46. **Figure 38**  
 47. **Figure 39**  
 48. **Figure 40**  
 49. **Figure 41**  
 50. **Figure 42**  
 51. **Figure 43**  
 52. **Figure 44**  
 53. **Figure 45**  
 54. **Figure 46**  
 55. **Figure 47**  
 56. **Figure 48**  
 57. **Figure 49**  
 58. **Figure 50**  
 59. **Figure 51**  
 60. **Figure 52**  
 61. **Figure 53**  
 62. **Figure 54**  
 63. **Figure 55**  
 64. **Figure 56**  
 65. **Figure 57**  
 66. **Figure 58**  
 67. **Figure 59**  
 68. **Figure 60**  
 69. **Figure 61**  
 70. **Figure 62**  
 71. **Figure 63**  
 72. **Figure 64**  
 73. **Figure 65**  
 74. **Figure 66**  
 75. **Figure 67**  
 76. **Figure 68**  
 77. **Figure 69**  
 78. **Figure 70**  
 79. **Figure 71**  
 80. **Figure 72**  
 81. **Figure 73**  
 82. **Figure 74**  
 83. **Figure 75**  
 84. **Figure 76**  
 85. **Figure 77**  
 86. **Figure 78**  
 87. **Figure 79**  
 88. **Figure 80**  
 89. **Figure 81**  
 90. **Figure 82**  
 91. **Figure 83**  
 92. **Figure 84**  
 93. **Figure 85**  
 94. **Figure 86**  
 95. **Figure 87**  
 96. **Figure 88**  
 97. **Figure 89**  
 98. **Figure 90**  
 99. **Figure 91**  
 100. **Figure 92**  
 101. **Figure 93**  
 102. **Figure 94**  
 103. **Figure 95**  
 104. **Figure 96**  
 105. **Figure 97**  
 106. **Figure 98**  
 107. **Figure 99**  
 108. **Figure 100**  
 109. **Figure 101**  
 110. **Figure 102**  
 111. **Figure 103**  
 112. **Figure 104**  
 113. **Figure 105**  
 114. **Figure 106**  
 115. **Figure 107**  
 116. **Figure 108**  
 117. **Figure 109**  
 118. **Figure 110**  
 119. **Figure 111**  
 120. **Figure 112**  
 121. **Figure 113**  
 122. **Figure 114**  
 123. **Figure 115**  
 124. **Figure 116**  
 125. **Figure 117**  
 126. **Figure 118**  
 127. **Figure 119**  
 128. **Figure 120**  
 129. **Figure 121**  
 130. **Figure 122**  
 131. **Figure 123**  
 132. **Figure 124**  
 133. **Figure 125**  
 134. **Figure 126**  
 135. **Figure 127**  
 136. **Figure 128**  
 137. **Figure 129**  
 138. **Figure 130**  
 139. **Figure 131**  
 140. **Figure 132**  
 141. **Figure 133**  
 142. **Figure 134**  
 143. **Figure 135**  
 144. **Figure 136**  
 145. **Figure 137**  
 146. **Figure 138**  
 147. **Figure 139**  
 148. **Figure 140**  
 149. **Figure 141**  
 150. **Figure 142**  
 151. **Figure 143**  
 152. **Figure 144**  
 153. **Figure 145**  
 154. **Figure 146**  
 155. **Figure 147**  
 156. **Figure 148**  
 157. **Figure 149**  
 158. **Figure 150**  
 159. **Figure 151**  
 160. **Figure 152**  
 161. **Figure 153**  
 162. **Figure 154**  
 163. **Figure 155**  
 164. **Figure 156**  
 165. **Figure 157**  
 166. **Figure 158**  
 167. **Figure 159**  
 168. **Figure 160**  
 169. **Figure 161**  
 170. **Figure 162**  
 171. **Figure 163**  
 172. **Figure 164**  
 173. **Figure 165**  
 174. **Figure 166**  
 175. **Figure 167**  
 176. **Figure 168**  
 177. **Figure 169**  
 178. **Figure 170**  
 179. **Figure 171**  
 180. **Figure 172**  
 181. **Figure 173**  
 182. **Figure 174**  
 183. **Figure 175**  
 184. **Figure 176**  
 185. **Figure 177**  
 186. **Figure 178**  
 187. **Figure 179**  
 188. **Figure 180**  
 189. **Figure 181**  
 190. **Figure 182**  
 191. **Figure 183**  
 192. **Figure 184**  
 193. **Figure 185**  
 194. **Figure 186**  
 195. **Figure 187**  
 196. **Figure 188**  
 197. **Figure 189**  
 198. **Figure 190**  
 199. **Figure 191**  
 200. **Figure 192**  
 201. **Figure 193**  
 202. **Figure 194**  
 203. **Figure 195**  
 204. **Figure 196**  
 205. **Figure 197**  
 206. **Figure 198**  
 207. **Figure 199**  
 208. **Figure 200**  
 209. **Figure 201**  
 210. **Figure 202**  
 211. **Figure 203**  
 212. **Figure 204**  
 213. **Figure 205**  
 214. **Figure 206**  
 215. **Figure 207**  
 216. **Figure 208**  
 217. **Figure 209**



PATENT

[MOBT:212]

[38-21(15579)A]

APPLICATION FOR UNITED STATES LETTERS PATENT

for

POLYHYDROXYALKANOATE BIOSYNTHESIS ASSOCIATED PROTEINS  
AND CODING REGION IN *BACILLUS MEGATERIUM*

by

*Maura C. Cannon*

*Francis C. Cannon*

*Gabriel J. McCool*

*Henry E. Valentin and*

*Kenneth J. Gruys*

EXPRESS MAIL MAILING LABEL

NUMBER: EL392859935US

DATE OF DEPOSIT: January 7, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington D.C. 20231.

*Lonnie Davis*

Signature

## FIELD OF THE INVENTION

The invention relates to nucleic acid and amino acid sequences involved in polyhydroxyalkanoate biosynthesis, and more specifically, to polyhydroxyalkanoate biosynthesis sequences isolated from *Bacillus megaterium*. In particular, nucleic acid sequences *phaP*, *phaQ*, *phaR*, *phaB*, *phaC*, and their encoded amino acid sequences are disclosed.

## BACKGROUND OF THE INVENTION

This patent application is related to U.S. Provisional Application Serial Number 60/115,092, filed on January 7, 1999. The government may own partial rights to the present invention pursuant to grant number MCB 9604450 from the National Science Foundation.

Polyhydroxyalkanoic acids (PHA) are a class of aliphatic polyesters that accumulate in inclusion-bodies in many bacteria and archaea (2, 41). Their physiological role in the cell is that of carbon and energy reserves, and as a sink for reducing power. The most studied PHA have repeating subunits of:  $-\text{[O-CH(R)(CH}_2\text{)}_x\text{CO]}-$ , where the most common form is polyhydroxybutyrate (PHB), with  $\text{R} = \text{CH}_3$  and  $x = 1$  (45). The PHA biosynthetic pathway has been determined for *Alcaligenes eutrophus* (17, 18, 44). In this organism two molecules of acetyl-Coenzyme A (CoA) are condensed by  $\beta$ -ketothiolase (PhaA), followed by a stereo-specific reduction catalyzed by an NADPH dependent acetoacetyl-CoA reductase (PhaB) to produce the monomer D-(-)- $\beta$ -hydroxybutyryl-CoA, which is polymerized by PHA synthase (PhaC). These 3 *pha* genes are coded on the *phaCAB* operon, which is speculated to be constitutively expressed, but PHA is not constitutively synthesized. Alternative pathways for synthesis of the monomer in other organisms have been suggested, most notably in the *Pseudomonas* species where the side chain, R, is longer than  $\text{CH}_3$  and its composition is influenced by carbon substrates in the growth medium (7, 45). In addition to *A. eutrophus*, *phaC* has been cloned from more than twenty different bacteria (26, 43). Other genes associated

with PHA synthesis, *phaA*, *phaB*, *phaZ* (PHA depolymerase) and genes for inclusion-body associated proteins and other low molecular weight proteins of unknown function, have also been cloned from some of these bacteria, in many cases by virtue of the fact that they are clustered with *phaC*.

PHA inclusion-bodies are 0.2 to 0.5 $\mu$ m in diameter, but their structural details are largely unknown. They were described originally for some species of *Bacillus* (6, 8, 15, 30, 47) and later for many more bacteria including *Pseudomonas*, *Alcaligenes* and *Rhodococcus* (5, 11, 12, 25, 42). Those from *Bacillus megaterium* were shown to contain 97.7% PHA, 1.87% protein and 0.46% lipid with protein and lipid forming an outer layer (15). More recent reports show the presence of a 14 kDa protein (GA14) on PHA inclusion-bodies of *R. ruber* (36, 37), and a 24 kDa protein (GA24) with similarities to GA14 on the inclusion-bodies of *A. eutrophus* (48). These proteins are not essential for PHA accumulation but have been shown to influence the size of PHA inclusion-bodies and the rate of PHA accumulation (37, 48). GA14 and GA24 have been named "phasins" due to some similarities with oleosins, which are proteins on the surface of oil bodies in plant seeds (21). Granule associated proteins are wide-spread in PHA accumulating bacteria (49).

The pattern of PHA inclusion-body growth and proliferation throughout the growth cycle of *Bacillus megaterium* has been described (32).

There exists a need for additional nucleic acid and amino acid sequences useful for the production of polymers in biological systems.

## SUMMARY OF THE INVENTION

This invention is the result of a study of PHA inclusion-body associated proteins from *Bacillus megaterium* and the cloning and analysis of their coding region. The transcription starts were identified, the functional expression of several of the sequences was confirmed in *Escherichia coli* and in PHA negative mutants of *Bacillus megaterium*

and *Pseudomonas putida*, and PhaP and PhaC were localized to PHA inclusion-bodies throughout growth.

A nucleic acid fragment encoding proteins involved in polyhydroxyalkanoate biosynthesis was isolated from *Bacillus megaterium*. Nine nucleic acid sequences and their encoded amino acid sequences are disclosed. Sequences encoding PhaB and PhaC display not insignificant percent identity and similarity to known acetoacetyl-CoA reductase and polyhydroxyalkanoate synthase proteins, while sequences encoding PhaP, PhaQ, and PhaR do not display significant similarity to known sequences. YkoY is similar to known toxic anion resistance proteins; YkoZ is similar to known RNA polymerase sigma factors; YkrM is similar to known Na<sup>+</sup>-transporting ATP synthase proteins; and SspD matches the known *B. megaterium* spore specific DNA binding protein.

While several PHA related sequences were expressed in two organisms, it is envisioned that the sequences may be expressed in a wide array of organisms, and that the nucleic acid sequences themselves may be modified to change the sequence and properties of the encoded proteins.

#### DESCRIPTION OF THE FIGURES

The following figures form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

Figure 1. PHA inclusion-body associated proteins. SDS-polyacrylamide gel electrophoresis of proteins released from purified PHA inclusion-bodies. Lane 1, molecular weight markers in kDa, 14, 18, 29, 43, 68 and 97. Lane 2, proteins from inclusion-bodies of cells harvested at late exponential growth phase. Lane 3, same as lane 2 except this part of the gel was stained following 45 minutes transfer of proteins (seen in lane 2) to PVDF membrane. The bands were visualized by staining with Coomassie Blue.

Figure 2 (A): The *pha* sequence cluster and flanking sequences. Map of cloned fragment in pGM10 carrying the *pha* genes (stripped arrows), intergenic regions (igrs) and flanking genes (thick black arrows) from *Bacillus megaterium*. The thin arrows indicate the locations and directions of transcripts; P, indicates promoter positions. pGM1, pGM6, pGM9 and pGM7 indicate the cloned DNA fragments in these plasmids (Table 1). Probes used to identify and clone the *pha* cluster are indicated by thick short lines under pGM1; n2 and n5 are degenerate probes; bmp and bmc are homologous probes to the ends of the pGM1 fragment. Ruler of sequence in base pairs is for *Bacillus megaterium* and *B. subtilis*. Map of *yko*, *sspD* and *ykr* region in the *B. subtilis* genome; genes with homology to those of *Bacillus megaterium* in this region are indicated by thick black arrows; non-homologous genes are indicated by thick gray arrows. Gene annotations are horizontal over each gene symbol. Relevant restriction enzyme sites are vertical.

Figure 2 (B): Putative promoter regions for *phaRBC*, *-Q*, *-P* and *sspD*. Curved arrows indicate transcription start (+1), -10 and -35 nucleotides. The closest resemblance to known -10 and -35 promoter sequences are in lower case letters below putative *pha* promoter sequences. Immediately downstream from the PhaP stop codon, the previously described (9) *sspD* putative promoter is boxed, and putative hairpin structure is underlined.

Figure 2 (C): Mapping of the 5' ends of the *phaRBC*, *-Q* and *-P* transcripts (see Example 11). Lanes G, A, T and C show the dideoxy sequencing ladders obtained with the same primers used in primer extension analysis; nucleotide sequences are complementary to the transcripts. Lane P is the primer extension product. Lane M is a DNA molecular size marker measured in nucleotides. The primer extension product is indicated by an arrowhead and the 5' end of the transcript within the sequence is indicated by a star. Only regions of the gel containing extension product bands are shown.

Figure 3: Pairwise alignment of PhaC from *Bacillus megaterium* (this study) and *P. oleovorans* (SWISS-PROT accession no. P26494); amino acid identities are shown in black. The Clustal method with PAM250 residue weight table was used.

Figure 4. *pha::gfp* fusion plasmids and precursors. Only relevant restriction sites are shown. Annotations are as Figure 2. In all fusions the c-terminus excluding the stop codon, of either *phaC* or *phaP*, is fused to the *gfp* gene by the pGFPuv polylinker. For more details, see Table 1.

Figure 5 (A): Time-course analysis of *Bacillus megaterium* (pGM16.2) by phase contrast, green fluorescence, light image, and PHA fluorescence. Time (hours) are hours post-inoculation as indicated.

Figure 5 (B): Growth curve for Figure 5 (A); arrowheads indicate a decrease in PhaP::GFP fluorescence.

Figure 5 (C): *Bacillus megaterium* (pGM16.2) sampled at 2 days post-inoculation. Top image is phase contrast, bottom image is GFP fluorescence.

Figure 5 (D): *Bacillus megaterium* (pGM13) sampled at 2 days post-inoculation, left -whole cells, right -lysed cells. Top image is phase contrast, bottom image is GFP fluorescence.

Figure 5 (E): *Bacillus megaterium* (pGM13C) sampled at 9 hours post-inoculation. Top image is phase contrast, bottom image is GFP fluorescence.

Figure 5 (F): *Bacillus megaterium* (pHPS9) showed no fluorescence at any time point. Top image is phase contrast, bottom image is GFP fluorescence.

Figure 6: Hydrophilicity plot of PhaP protein.

Figure 7: Hydrophilicity plot of PhaQ protein.

Figure 8: Hydrophilicity plot of PhaR protein.

Figure 9: Pairwise alignment of PhaC from *Bacillus megaterium* (this study) and *T. violacea* (SWISS-PROT accession no. P45366); amino acid identities are indicated by a star (\*), and amino acid similarities are indicated by a period (.) below the sequences. The ClustalW method with PAM350 residue weight table was used.

Figure 10: Proposed biosynthetic pathway for the preparation of C8 copolymers.

## DESCRIPTION OF THE SEQUENCE LISTINGS

The following sequence listings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these sequences in combination with the detailed description of specific embodiments presented herein.

SEQ ID NO	Description
1	<i>Bacillus megaterium</i> 7,916 bp fragment
2	<i>phaP</i> nucleic acid sequence, 2566-3075 reverse complement
3	PhaP amino acid sequence, 170 amino acids
4	<i>phaQ</i> nucleic acid sequence, 3247-3684 reverse complement
5	PhaQ amino acid sequence, 146 amino acids
6	<i>phaR</i> nucleic acid sequence, 4170-4673
7	PhaR amino acid sequence, 168 amino acids
8	<i>phaB</i> nucleic acid sequence, 4758-5498
9	PhaB amino acid sequence, 247 amino acids
10	<i>phaC</i> nucleic acid sequence, 5578-6663
11	PhaC amino acid sequence, 362 amino acids
12	oligonucleotide probe n2, 39 bases
13	oligonucleotide probe n5, 30 bases
14	oligonucleotide probe bmp, 19 bases
15	oligonucleotide probe bmc, 22 bases
16	oligonucleotide primer for <i>phaP</i> transcription start, 20 bases
17	oligonucleotide primer for <i>phaQ</i> transcription start, 19 bases
18	oligonucleotide primer for <i>phaRBC</i> transcription start, 19 bases
19	N-terminal amino acid sequence of 14 kDa protein
20	N-terminal amino acid sequence of 20 kDa protein
21	N-terminal amino acid sequence of 41 kDa protein
22	<i>ykoY</i> nucleic acid sequence, 277-1089
23	YkoY amino acid sequence, 271 amino acids
24	<i>ykoZ</i> nucleic acid sequence, 1460-2167
25	YkoZ amino acid sequence, 236 amino acids
26	<i>ykrM</i> nucleic acid sequence, 6959-7916 (partial)
27	YkrM amino acid sequence, 319 amino acids (partial)
28	<i>sspD</i> nucleic acid sequence, 2419-2225 reverse complement
29	SspD amino acid sequence, 65 amino acids

## DEFINITIONS

The following definitions are provided in order to aid those skilled in the art in understanding the detailed description of the present invention.

“C-terminal region” refers to the region of a peptide, polypeptide, or protein chain from the middle thereof to the end that carries the amino acid having a free a carboxyl group (the C-terminus).

“CoA” refers to coenzyme A.

The phrases “coding sequence”, “open reading frame”, and “structural sequence” refer to the region of continuous sequential nucleic acid triplets encoding a protein, polypeptide, or peptide sequence.

The term “encoding DNA” or “encoding nucleic acid” refers to chromosomal nucleic acid, plasmid nucleic acid, cDNA, or synthetic nucleic acid which codes on expression for any of the proteins or fusion proteins discussed herein.

The term “genome” as it applies to bacteria encompasses both the chromosome and plasmids within a bacterial host cell. Encoding nucleic acids of the present invention introduced into bacterial host cells can therefore be either chromosomally-integrated or plasmid-localized. The term “genome” as it applies to plant cells encompasses not only chromosomal DNA found within the nucleus, but organelle DNA found within subcellular components of the cell. Nucleic acids of the present invention introduced into plant cells can therefore be either chromosomally-integrated or organelle-localized.

“Identity” refers to the degree of similarity between two nucleic acid or protein sequences. An alignment of the two sequences is performed by a suitable computer program. A widely used and accepted computer program for performing sequence alignments is CLUSTALW v1.6 (Thompson, et al. *Nucl. Acids Res.*, 22: 4673-4680, 1994). The number of matching bases or amino acids is divided by the total number of bases or amino acids, and multiplied by 100 to obtain a percent identity. For example, if two 580 base pair sequences had 145 matched bases, they would be 25 percent identical. If the two compared sequences are of different lengths, the number of matches is divided

by the shorter of the two lengths. For example, if there were 100 matched amino acids between 200 and a 400 amino acid proteins, they are 50 percent identical with respect to the shorter sequence. If the shorter sequence is less than 150 bases or 50 amino acids in length, the number of matches are divided by 150 (for nucleic acids) or 50 (for proteins); and multiplied by 100 to obtain a percent identity.

The terms “microbe” or “microorganism” refer to algae, bacteria, fungi, and protozoa.

“N-terminal region” refers to the region of a peptide, polypeptide, or protein chain from the amino acid having a free amino group to the middle of the chain.

“Nucleic acid” refers to ribonucleic acid (RNA) and deoxyribonucleic acid (DNA).

A “nucleic acid segment” is a nucleic acid molecule that has been isolated free of total genomic DNA of a particular species, or that has been synthesized. Included with the term “nucleic acid segment” are DNA segments, recombinant vectors, plasmids, cosmids, phagemids, phage, viruses, etcetera.

“Overexpression” refers to the expression of a polypeptide or protein encoded by a DNA introduced into a host cell, wherein said polypeptide or protein is either not normally present in the host cell, or wherein said polypeptide or protein is present in said host cell at a higher level than that normally expressed from the endogenous gene encoding said polypeptide or protein.

The term “plastid” refers to the class of plant cell organelles that includes amyloplasts, chloroplasts, chromoplasts, elaioplasts, eoplasts, etioplasts, leucoplasts, and proplastids. These organelles are self-replicating, and contain what is commonly referred to as the “chloroplast genome,” a circular DNA molecule that ranges in size from about 120 to about 217 kb, depending upon the plant species, and which usually contains an inverted repeat region (Fosket, Plant growth and Development, Academic Press, Inc., San Diego, CA, p. 132, 1994).

“Polyadenylation signal” or “polyA signal” refers to a nucleic acid sequence located 3’ to a coding region that directs the addition of adenylate nucleotides to the 3’ end of the mRNA transcribed from the coding region.

The term “polyhydroxyalkanoate (or PHA) synthase” refers to enzymes that  
5 convert hydroxyacyl-CoAs to polyhydroxyalkanoates and free CoA.

The term “promoter” or “promoter region” refers to a nucleic acid sequence, usually found upstream (5’) to a coding sequence, that controls expression of the coding sequence by controlling production of messenger RNA (mRNA) by providing the recognition site for RNA polymerase and/or other factors necessary for start of  
10 transcription at the correct site. As contemplated herein, a promoter or promoter region includes variations of promoters derived by means of ligation to various regulatory sequences, random or controlled mutagenesis, and addition or duplication of enhancer sequences. The promoter region disclosed herein, and biologically functional equivalents thereof, are responsible for driving the transcription of coding sequences under their  
15 control when introduced into a host as part of a suitable recombinant vector, as demonstrated by its ability to produce mRNA.

“Regeneration” refers to the process of growing a plant from a plant cell (e.g., plant protoplast or explant).

“Transformation” refers to a process of introducing an exogenous nucleic acid  
20 sequence (e.g., a vector, recombinant nucleic acid molecule) into a cell or protoplast in which that exogenous nucleic acid is incorporated into a chromosome or is capable of autonomous replication.

A “transformed cell” is a cell whose nucleic acid has been altered by the introduction of an exogenous nucleic acid molecule into that cell.

25 A “transformed plant” or “transgenic plant” is a plant whose nucleic acid has been altered by the introduction of an exogenous nucleic acid molecule into that plant, or by the introduction of an exogenous nucleic acid molecule into a plant cell from which the plant was regenerated or derived.

## DETAILED DESCRIPTION OF THE INVENTION

This invention was developed in the pursuit of proteins which are associated with polyhydroxyalkanoate inclusion bodies, and in the pursuit of novel nucleic acid and amino acid sequences from the bacteria *Bacillus megaterium*. A 7,916 base pair nucleic acid fragment was isolated and sequenced (SEQ ID NO:1). This fragment was found to contain nine open reading frames, five of which encode proteins suspected of being involved in polyhydroxyalkanoate biosynthesis.

### Genomic fragment

An embodiment of the invention is a nucleic acid segment at least about 80% identical to SEQ ID NO:1. More preferably, the nucleic acid segment is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:1. Alternatively, the nucleic acid segment may be a nucleic acid segment that hybridizes under stringent conditions to SEQ ID NO:1, or to the complement thereof. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic.

The invention is further directed to nucleic acid segments, proteins, recombinant vectors, recombinant host cells, genetically transformed plant cells, genetically transformed plants, methods of preparing host cells, methods of preparing plants, fusion proteins, and nucleic acid segments encoding fusion proteins.

### *phaP* and PhaP

A nucleic acid segment may comprise a nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:2; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:2 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:3; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:3 as an antigen, the antibody being immunoreactive with SEQ ID NO:3. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%,

98%, 99%, 99.5%, or 100% identical to SEQ ID NO:2. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:3.

An isolated polyhydroxyalkanoate inclusion body associated protein may comprise an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:3; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:3 as an antigen, the antibody being immunoreactive with SEQ ID NO:3. The protein is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:3

A recombinant vector may comprise in the 5' to 3' direction: a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:2; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:2 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:3; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:3 as an antigen, the antibody being immunoreactive with SEQ ID NO:3; and c) a 3' transcription terminator. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:2. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:3. The promoter may generally be any

promoter, and more preferably is a tissue selective or tissue specific promoter. The promoter may be constitutive or inducible. The promoter may be a viral promoter. The promoter may be a CMV35S, enhanced CMV35S, an FMV35S, a *Lesquerella* hydroxylase, or a 7S conglycinin promoter.

5 A recombinant host cell may comprise a nucleic acid segment encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the nucleic acid segment is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:2; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:2 or the complement thereof; a nucleic acid sequence encoding  
10 a protein at least about 80% identical to SEQ ID NO:3; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:3 as an antigen, the antibody being immunoreactive with SEQ ID NO:3. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:2. The nucleic acid segment may be  
15 obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:3. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is  
20 preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

25 A genetically transformed plant cell may comprise in the 5' to 3' direction: a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic

acid sequence at least about 80% identical to SEQ ID NO:2; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:2 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:3; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:3 as an antigen, the antibody being immunoreactive with SEQ ID NO:3; c) a 3' transcription terminator; and d) a 3' polyadenylation signal sequence that directs the addition of polyadenylate nucleotides to the 3' end of RNA transcribed from the structural nucleic acid sequence. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:2. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:3. The plant may generally be any plant, and more preferably a monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

A method of preparing host cells useful to produce a polyhydroxyalkanoate inclusion body associated protein may comprise a) selecting a host cell; b) transforming the selected host cell with a recombinant vector having a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:2; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:2 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:3; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:3 as an antigen, the antibody being immunoreactive with SEQ ID NO:3; and c) obtaining transformed host cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%,

99.5%, or 100% identical to SEQ ID NO:2. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:3. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

A method of preparing plants useful to produce a polyhydroxyalkanoate inclusion body associated protein may comprise a) selecting a host plant cell; b) transforming the selected host plant cell with a recombinant vector having a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:2; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:2 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:3; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:3 as an antigen, the antibody being immunoreactive with SEQ ID NO:3; c) obtaining transformed host plant cells; and d) regenerating the transformed host plant cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:2. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:3. The plant (and plant cell) may generally be any plant, and more preferably a

monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

The invention also relates to fusion proteins. A fusion protein may comprise a green fluorescent protein subunit; and a polyhydroxyalkanoate inclusion body associated protein subunit; wherein the polyhydroxyalkanoate inclusion body associated protein subunit comprises an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:3; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:3 as an antigen, the antibody being immunoreactive with SEQ ID NO:3. The polyhydroxyalkanoate inclusion body associated protein subunit is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:3

A nucleic acid segment encoding a fusion protein may comprise a nucleic acid sequence encoding a green fluorescent protein subunit; and a nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein subunit; wherein the nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein subunit is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:2; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:2 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:3; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:3 as an antigen, the antibody being immunoreactive with SEQ ID NO:3. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:2. The nucleic acid sequence may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein subunit at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:3.

phaQ and PhaQ

A nucleic acid segment may comprise a nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:4; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:4 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:5; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:5 as an antigen, the antibody being immunoreactive with SEQ ID NO:5. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:4. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:5.

An isolated polyhydroxyalkanoate inclusion body associated protein may comprise an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:5; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:5 as an antigen, the antibody being immunoreactive with SEQ ID NO:5. The protein is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:5

A recombinant vector may comprise in the 5' to 3' direction: a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:4; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:4 or the complement thereof; a

nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:5; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:5 as an antigen, the antibody being immunoreactive with SEQ ID NO:5; and c) a 3' transcription terminator. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:4. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:5. The promoter may generally be any promoter, and more preferably is a tissue selective or tissue specific promoter. The promoter may be constitutive or inducible. The promoter may be a viral promoter. The promoter may be a CMV35S, enhanced CMV35S, an FMV35S, a *Lesquerella* hydroxylase, or a 7S conglycinin promoter.

A recombinant host cell may comprise a nucleic acid segment encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the nucleic acid segment is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:4; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:4 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:5; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:5 as an antigen, the antibody being immunoreactive with SEQ ID NO:5. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:4. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:5. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is

preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

A genetically transformed plant cell may comprise in the 5' to 3' direction: a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:4; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:4 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:5; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:5 as an antigen, the antibody being immunoreactive with SEQ ID NO:5; c) a 3' transcription terminator; and d) a 3' polyadenylation signal sequence that directs the addition of polyadenylate nucleotides to the 3' end of RNA transcribed from the structural nucleic acid sequence. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:4. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:5. The plant may generally be any plant, and more preferably a monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

A method of preparing host cells useful to produce a polyhydroxyalkanoate inclusion body associated protein may comprise a) selecting a host cell; b) transforming

the selected host cell with a recombinant vector having a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:4; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:4 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:5; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:5 as an antigen, the antibody being immunoreactive with SEQ ID NO:5; and c) obtaining transformed host cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:4. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:5. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

A method of preparing plants useful to produce a polyhydroxyalkanoate inclusion body associated protein may comprise a) selecting a host plant cell; b) transforming the selected host plant cell with a recombinant vector having a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:4; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:4 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:5;

and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:5 as an antigen, the antibody being immunoreactive with SEQ ID NO:5; c) obtaining transformed host plant cells; and d) regenerating the transformed host plant cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:4. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:5. The plant (and plant cell) may generally be any plant, and more preferably a monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

The invention also relates to fusion proteins. A fusion protein may comprise a green fluorescent protein subunit; and a polyhydroxyalkanoate inclusion body associated protein subunit; wherein the polyhydroxyalkanoate inclusion body associated protein subunit comprises an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:5; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:5 as an antigen, the antibody being immunoreactive with SEQ ID NO:5. The polyhydroxyalkanoate inclusion body associated protein subunit is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:5

A nucleic acid segment encoding a fusion protein may comprise a nucleic acid sequence encoding a green fluorescent protein subunit; and a nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein subunit; wherein the nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein subunit is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:4; a nucleic acid sequence that hybridizes under

stringent conditions to SEQ ID NO:4 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:5; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:5 as an antigen, the antibody being immunoreactive with SEQ ID NO:5. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:4. The nucleic acid sequence may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein subunit at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:5.

*phaR* and *PhaR*

A nucleic acid segment may comprise a nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:6; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:6 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:7; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:7 as an antigen, the antibody being immunoreactive with SEQ ID NO:7. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:6. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:7.

An isolated polyhydroxyalkanoate inclusion body associated protein may comprise an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:7; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:7 as an antigen, the

antibody being immunoreactive with SEQ ID NO:7. The protein is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:7

A recombinant vector may comprise in the 5' to 3' direction: a) a promoter that  
5 directs transcription of a structural nucleic acid sequence encoding a  
polyhydroxyalkanoate inclusion body associated protein; b) a structural nucleic acid  
sequence encoding a polyhydroxyalkanoate inclusion body associated protein; wherein  
the structural nucleic acid sequence is selected from the group consisting of: a nucleic  
acid sequence at least about 80% identical to SEQ ID NO:6; a nucleic acid sequence that  
10 hybridizes under stringent conditions to SEQ ID NO:6 or the complement thereof; a  
nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:7;  
and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody  
prepared using SEQ ID NO:7 as an antigen, the antibody being immunoreactive with  
SEQ ID NO:7; and c) a 3' transcription terminator. More preferably, the nucleic acid  
15 sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%,  
99.5%, or 100% identical to SEQ ID NO:6. The nucleic acid segment may be obtained  
from a natural source, may be mutagenized, may be genetically engineered by  
mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably  
encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%,  
20 99.5%, or 100% identical to SEQ ID NO:7. The promoter may generally be any  
promoter, and more preferably is a tissue selective or tissue specific promoter. The  
promoter may be constitutive or inducible. The promoter may be a viral promoter. The  
promoter may be a CMV35S, enhanced CMV35S, an FMV35S, a *Lesquerella*  
hydroxylase, or a 7S conglycinin promoter.

25 A recombinant host cell may comprise a nucleic acid segment encoding a  
polyhydroxyalkanoate inclusion body associated protein, wherein the nucleic acid  
segment is selected from the group consisting of: a nucleic acid sequence at least about  
80% identical to SEQ ID NO:6; a nucleic acid sequence that hybridizes under stringent  
conditions to SEQ ID NO:6 or the complement thereof; a nucleic acid sequence encoding

004095-010000

a protein at least about 80% identical to SEQ ID NO:7; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:7 as an antigen, the antibody being immunoreactive with SEQ ID NO:7. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:6. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:7. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

A genetically transformed plant cell may comprise in the 5' to 3' direction: a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein; wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:6; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:6 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:7; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:7 as an antigen, the antibody being immunoreactive with SEQ ID NO:7; c) a 3' transcription terminator; and d) a 3' polyadenylation signal sequence that directs the addition of polyadenylate nucleotides to the 3' end of RNA transcribed from the structural nucleic acid sequence. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%,

99.5%, or 100% identical to SEQ ID NO:6. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:7. The plant may generally be any plant, and more preferably a monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

A method of preparing host cells useful to produce a polyhydroxyalkanoate inclusion body associated protein may comprise a) selecting a host cell; b) transforming the selected host cell with a recombinant vector having a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:6; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:6 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:7; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:7 as an antigen, the antibody being immunoreactive with SEQ ID NO:7; and c) obtaining transformed host cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:6. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:7. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants

such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

A method of preparing plants useful to produce a polyhydroxyalkanoate inclusion body associated protein may comprise a) selecting a host plant cell; b) transforming the selected host plant cell with a recombinant vector having a structural nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:6; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:6 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:7; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:7 as an antigen, the antibody being immunoreactive with SEQ ID NO:7; c) obtaining transformed host plant cells; and d) regenerating the transformed host plant cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:6. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:7. The plant (and plant cell) may generally be any plant, and more preferably a monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

The invention also relates to fusion proteins. A fusion protein may comprise a green fluorescent protein subunit; and a polyhydroxyalkanoate inclusion body associated protein subunit; wherein the polyhydroxyalkanoate inclusion body associated protein subunit comprises an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:7; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:7 as an

antigen, the antibody being immunoreactive with SEQ ID NO:7. The polyhydroxyalkanoate inclusion body associated protein subunit is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:7

5 A nucleic acid segment encoding a fusion protein may comprise a nucleic acid sequence encoding a green fluorescent protein subunit; and a nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein subunit; wherein the nucleic acid sequence encoding a polyhydroxyalkanoate inclusion body associated protein subunit is selected from the group consisting of: a nucleic acid sequence at least  
10 about 80% identical to SEQ ID NO:6; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:6 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:7; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:7 as an antigen, the antibody being immunoreactive with SEQ ID NO:7. More  
15 preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:6. The nucleic acid sequence may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein subunit at least about 82%, 84%, 86%,  
20 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:7.

#### *phaB* and PhaB

A nucleic acid segment may comprise a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein, wherein the nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a  
25 nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9. More preferably, the nucleic acid

002010 04062460

sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9.

An isolated 3-keto-acyl-CoA reductase protein may comprise an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:9; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9. The protein is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9

A recombinant vector may comprise in the 5' to 3' direction: a) a promoter that directs transcription of a structural nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; b) a structural nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and c) a 3' transcription terminator. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9. The promoter may generally be any promoter, and more preferably is a tissue selective or

002070-04062460

tissue specific promoter. The promoter may be constitutive or inducible. The promoter may be a viral promoter. The promoter may be a CMV35S, enhanced CMV35S, an FMV35S, a *Lesquerella* hydroxylase, or a 7S conglycinin promoter.

A recombinant host cell may comprise a nucleic acid segment encoding a 3-keto-acyl-CoA reductase protein, wherein the nucleic acid segment is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

A genetically transformed plant cell may comprise in the 5' to 3' direction: a) a promoter that directs transcription of a structural nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; b) a structural nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8

or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; c) a 3' transcription terminator; and  
5 d) a 3' polyadenylation signal sequence that directs the addition of polyadenylate nucleotides to the 3' end of RNA transcribed from the structural nucleic acid sequence. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be  
10 genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9. The plant may generally be any plant, and more preferably a monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn,  
15 soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

A method of preparing host cells useful to produce a 3-keto-acyl-CoA reductase protein may comprise a) selecting a host cell; b) transforming the selected host cell with a recombinant vector having a structural nucleic acid sequence encoding a 3-keto-acyl-CoA  
20 reductase protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is  
25 immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and c) obtaining transformed host cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may

be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

A method of preparing plants useful to produce a 3-keto-acyl-CoA reductase protein may comprise a) selecting a host plant cell; b) transforming the selected host plant cell with a recombinant vector having a structural nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; c) obtaining transformed host plant cells; and d) regenerating the transformed host plant cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9. The plant (and plant cell) may generally be any plant, and more preferably a monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean,

canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

The invention also relates to fusion proteins. A fusion protein may comprise a green fluorescent protein subunit; and a 3-keto-acyl-CoA reductase protein subunit; wherein the 3-keto-acyl-CoA reductase protein subunit comprises an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:9; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9. The 3-keto-acyl-CoA reductase protein subunit is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9

A nucleic acid segment encoding a fusion protein may comprise a nucleic acid sequence encoding a green fluorescent protein subunit; and a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein subunit; wherein the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein subunit is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid sequence may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein subunit at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9.

phaC and PhaC

A nucleic acid segment may comprise a nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein, wherein the nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11.

An isolated polyhydroxyalkanoate synthase protein may comprise an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:11; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11. The protein is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11

A recombinant vector may comprise in the 5' to 3' direction: a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein; b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein; wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence

03475040-010700

encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and c) a 3' transcription terminator. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11. The promoter may generally be any promoter, and more preferably is a tissue selective or tissue specific promoter. The promoter may be constitutive or inducible. The promoter may be a viral promoter. The promoter may be a CMV35S, enhanced CMV35S, an FMV35S, a *Lesquerella* hydroxylase, or a 7S conglycinin promoter.

A recombinant host cell may comprise a nucleic acid segment encoding a polyhydroxyalkanoate synthase protein, wherein the nucleic acid segment is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The

002070-040460

fungus cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

5 A genetically transformed plant cell may comprise in the 5' to 3' direction: a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein; b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein; wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; c) a 3' transcription terminator; and d) a 3' polyadenylation signal sequence that directs the addition of polyadenylate nucleotides to the 3' end of RNA transcribed from the structural nucleic acid sequence. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11. The plant may generally be any plant, and more preferably a monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

A method of preparing host cells useful to produce a polyhydroxyalkanoate synthase protein may comprise a) selecting a host cell; b) transforming the selected host cell with a recombinant vector having a structural nucleic acid sequence encoding a

polyhydroxyalkanoate synthase protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and c) obtaining transformed host cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11. The host cell may generally be any host cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell.

A method of preparing plants useful to produce a polyhydroxyalkanoate synthase protein may comprise a) selecting a host plant cell; b) transforming the selected host plant cell with a recombinant vector having a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein, wherein the structural nucleic acid sequence is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; c)

obtaining transformed host plant cells; and d) regenerating the transformed host plant cells. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid segment may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11. The plant (and plant cell) may generally be any plant, and more preferably a monocot, dicot, or conifer. The plant is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant.

The invention also relates to fusion proteins. A fusion protein may comprise a green fluorescent protein subunit; and a polyhydroxyalkanoate synthase protein subunit; wherein the polyhydroxyalkanoate synthase protein subunit comprises an amino acid sequence selected from the group consisting of: an amino acid sequence at least about 80% identical to SEQ ID NO:11; and an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11. The polyhydroxyalkanoate synthase protein subunit is preferably at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11

A nucleic acid segment encoding a fusion protein may comprise a nucleic acid sequence encoding a green fluorescent protein subunit; and a nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein subunit; wherein the nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein subunit is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the

antibody being immunoreactive with SEQ ID NO:11. More preferably, the nucleic acid sequence is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid sequence may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence preferably encodes a protein subunit at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11.

PHA biosynthesis methods: *phaB* and *phaC*

A method for the preparation of polyhydroxyalkanoate may comprise: a) obtaining a cell comprising: a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; and a nucleic acid sequence encoding a PHA synthase protein; wherein: the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is not naturally found in the cell; the nucleic acid sequence encoding a PHA synthase protein is not naturally found in the cell; the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and the nucleic acid sequence encoding a PHA synthase protein is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and b) culturing the cell under conditions suitable for the preparation of polyhydroxyalkanoate. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein more preferably is at least about

82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9. The nucleic acid sequence encoding a PHA synthase protein more preferably is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid sequence encoding a PHA synthase protein may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence encoding a PHA synthase protein preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11. The cell may generally be any cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell. The polyhydroxyalkanoate may be a homopolymer or copolymer. The polyhydroxyalkanoate may be a polyhydroxybutyrate, polyhydroxyvalerate, polyhydroxyhexanoate, polyhydroxyoctanoate, polyhydroxydecanoate, or copolymers thereof.

A method for the preparation of polyhydroxyalkanoate may comprise: a) obtaining a plant comprising: a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; and a nucleic acid sequence encoding a PHA synthase protein; wherein: the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is not naturally found in the plant; the nucleic acid sequence encoding a PHA synthase protein is not naturally found in the plant; the nucleic acid sequence encoding a 3-keto-acyl-CoA

reductase protein is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and the nucleic acid sequence encoding a PHA synthase protein is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and b) growing the plant under conditions suitable for the preparation of polyhydroxyalkanoate. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein more preferably is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9. The nucleic acid sequence encoding a PHA synthase protein more preferably is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid sequence encoding a PHA synthase protein may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence encoding a PHA synthase protein preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11. The plant is preferably a tobacco, wheat, potato,

*Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant. The polyhydroxyalkanoate may be a homopolymer or copolymer. The polyhydroxyalkanoate may be a polyhydroxybutyrate, polyhydroxyvalerate, polyhydroxyhexanoate, polyhydroxyoctanoate, polyhydroxydecanoate, or copolymers thereof.

PHA biosynthesis methods: *phaB*

A method for the preparation of polyhydroxyalkanoate may comprise: a) obtaining a cell comprising: a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; and a nucleic acid sequence encoding a PHA synthase protein; wherein: the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is not naturally found in the cell; the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and b) culturing the cell under conditions suitable for the preparation of polyhydroxyalkanoate. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein more preferably is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9. The cell may generally be any cell, and preferably is a bacterial, fungal, mammalian, or plant cell. The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant

cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell. The polyhydroxyalkanoate may be a homopolymer or copolymer. The polyhydroxyalkanoate may be a polyhydroxybutyrate, polyhydroxyvalerate, polyhydroxyhexanoate, polyhydroxyoctanoate, polyhydroxydecanoate, or copolymers thereof.

A method for the preparation of polyhydroxyalkanoate may comprise: a) obtaining a plant comprising: a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; and a nucleic acid sequence encoding a PHA synthase protein; wherein: the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is not naturally found in the plant; the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and b) growing the plant under conditions suitable for the preparation of polyhydroxyalkanoate. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein more preferably is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:8. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:9. The plant may generally be any plant, and preferably is a tobacco, wheat, potato, *Arabidopsis*, high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant. The polyhydroxyalkanoate may be a homopolymer or copolymer. The

polyhydroxyalkanoate may be a polyhydroxybutyrate, polyhydroxyvalerate, polyhydroxyhexanoate, polyhydroxyoctanoate, polyhydroxydecanoate, or copolymers thereof.

PHA biosynthesis methods: *phaC*

5 A method for the preparation of polyhydroxyalkanoate may comprise: a) obtaining a cell comprising: a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; and a nucleic acid sequence encoding a PHA synthase protein; wherein: the nucleic acid sequence encoding a PHA synthase protein is not naturally found in the cell; the nucleic acid sequence encoding a PHA synthase protein is selected  
10 from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the  
15 antibody being immunoreactive with SEQ ID NO:11; and b) culturing the cell under conditions suitable for the preparation of polyhydroxyalkanoate. The nucleic acid sequence encoding a PHA synthase protein more preferably is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid sequence encoding a PHA synthase protein may be obtained  
20 from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence encoding a PHA synthase protein preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11. The cell may generally be any cell, and preferably is a bacterial, fungal, mammalian, or plant cell.  
25 The bacterial cell is preferably an *Escherichia coli*, *Bacillus*, *Pseudomonas*, or *Ralstonia eutropha* cell. The fungal cell is preferably a *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe* cell. The plant cell is preferably a tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa cell. The

polyhydroxyalkanoate may be a homopolymer or copolymer. The polyhydroxyalkanoate may be a polyhydroxybutyrate, polyhydroxyvalerate, polyhydroxyhexanoate, polyhydroxyoctanoate, polyhydroxydecanoate, or copolymers thereof.

A method for the preparation of polyhydroxyalkanoate may comprise: a) obtaining a plant comprising: a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; and a nucleic acid sequence encoding a PHA synthase protein; wherein: the nucleic acid sequence encoding a PHA synthase protein is not naturally found in the plant; the nucleic acid sequence encoding a PHA synthase protein is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:10; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and b) growing the plant under conditions suitable for the preparation of polyhydroxyalkanoate. The nucleic acid sequence encoding a PHA synthase protein more preferably is at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:10. The nucleic acid sequence encoding a PHA synthase protein may be obtained from a natural source, may be mutagenized, may be genetically engineered by mutagenesis or other methods, or may be synthetic. The nucleic acid sequence encoding a PHA synthase protein preferably encodes a protein at least about 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, 99.5%, or 100% identical to SEQ ID NO:11. The plant may generally be any plant, and preferably is a tobacco, wheat, potato, *Arabidopsis*, high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, or alfalfa plant. The polyhydroxyalkanoate may be a homopolymer or copolymer. The polyhydroxyalkanoate may be a polyhydroxybutyrate, polyhydroxyvalerate, polyhydroxyhexanoate, polyhydroxyoctanoate, polyhydroxydecanoate, or copolymers thereof.

### Methods for preparing higher polyhydroxyalkanoates

Polyhydroxyalkanoate may be prepared by a method comprising: a) obtaining a recombinant host cell comprising: a nucleic acid sequence encoding a  $\beta$ -ketothiolase protein; a nucleic acid sequence encoding a 3-ketoacyl-CoA reductase protein; a nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein; a nucleic acid sequence encoding a  $\beta$ -hydroxyacyl-CoA dehydrase; and a nucleic acid sequence encoding an acyl-CoA dehydrogenase protein or an enoyl-CoA reductase protein; and b) culturing the recombinant host cell under conditions suitable for the preparation of polyhydroxyalkanoate; wherein: the polyhydroxyalkanoate comprises C6, C8, or C10 monomer subunits; the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is selected from the group consisting of: a nucleic acid sequence at least about 80% identical to SEQ ID NO:8; a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof; a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9.

### Primers, probes, and antibodies

The sequences disclosed in the sequence listing may also be used to prepare primers, probes, and monoclonal or polyclonal antibodies.

SEQ ID NOS:1, 2, 4, 6, 8, 10, 22, 24, 26, and 28, and the their complementary strands may be used to design oligonucleotide primers and probes. Primers and probes are typically at least 15 nucleotides in length, and more preferably are at least 20, 22, 24, 26, 28, 30, 40, or 50 nucleotides in length. Contiguous nucleotide sequences from a given sequence are chosen based upon favorable hybridization conditions, including minimization of hairpin or other detrimental sequences. The identification of suitable primer or probe sequences is well known to those of skill in the art, and is facilitated by commercially available software such as MacVector (Oxford Molecular Group) and Xprimer (<http://alces.med.umn.edu/rawprimer.html>). Primers and probes may be used for

the screening of libraries, for PCR amplification, and other routine molecular biological applications. Primers and probes may also be used for antisense applications.

SEQ ID NOS:3, 5, 7, 9, 11, 23, 25, 27, and 29 may be used for the generation of monoclonal or polyclonal antibodies. The entire sequences may be used, or antigenic fragments thereof. Alternatively, portions of the full length sequences may be synthesized and covalently attached to antigenic proteins such as keyhole limpet hemocyanin (KLH). Portions of the full length sequences may be used for the preparation of multi-antigenic peptides (52). The generation of monoclonal and polyclonal antibodies is well known to those of skill in the art.

The following Examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

SECRET

### Example 1: Bacterial strains and plasmids

Table 1. Strains

Strains	Relevant characteristics <sup>a</sup>	Source or Reference
<i>E. coli</i> DH5 $\alpha$	<i>deoR endA1 gyrA96 hsdR17</i> ( $r_k^- m_k^+$ ) <i>recA1 relA1 supE44 thi-1</i> $\Delta$ ( <i>lacZYA-argFV169</i> ) $\phi$ 80 <i>lacZ</i> $\Delta$ M15 F' $\lambda^-$ . Cloning host and for expression of <i>pha</i> genes	Clontech
<i>B. megaterium</i> 11561	Wild type, used to clone <i>pha</i> genes	ATCC <sup>b</sup>
<i>B. megaterium</i> PHA05	<i>phaP</i> , <i>-Q</i> , <i>-R</i> , <i>-B</i> and <i>-C</i> deletion derivative of <i>B. megaterium</i> 11561	This Application
<i>P. oleovorans</i> 29347	PHA positive control	ATCC
<i>P. putida</i> GPp104	PHA negative mutant obtained by chemical mutagenesis	(22)

Table 2. Plasmids

Plasmids	Relevant characteristics <sup>a</sup>	Source or Reference
pBluescriptIIISK	Cloning vector, ColE1 oriV <sup>c</sup> , Amp <sup>r</sup>	Stratagene
pGFPuv	Source of <i>gfp</i> gene, ColE1 oriV, Amp <sup>r</sup>	Clontech
pHPS9	<i>Bacillus-Escherichia coli</i> shuttle vector, ColE1 and pTA1060 oriV, Em <sup>r</sup> , Cm <sup>r</sup>	(16)
pSUP104	<i>Pseudomonas-Escherichia coli</i> shuttle vector, Q-type and mini15 oriV, Em <sup>r</sup> , Tc <sup>r</sup>	(40)
pGM1	<i>EcoRI</i> in <i>phaP</i> to <i>HindIII</i> in <i>phaC</i> , cloned into the <i>EcoRI-HindIII</i> sites of pBluescriptIIISK, Amp <sup>r</sup>	This application
pGM6	<i>PstI</i> in <i>phaB</i> to <i>EcoRI</i> in <i>ykrM</i> , cloned into the <i>PstI-EcoRI</i> sites of pBluescriptIIISK, Amp <sup>r</sup>	This application
pGM7	<i>EcoRI</i> in <i>phaP</i> to <i>EcoRI</i> in <i>ykrM</i> , cloned into the <i>EcoRI</i> site of pBluescriptIIISK, Amp <sup>r</sup>	This application
pGM9	<i>HindIII</i> upstream of <i>ykoY</i> to <i>PstI</i> in <i>phaB</i> , cloned into the <i>HindIII -PstI</i> sites of pBluescriptIIISK, Amp <sup>r</sup>	This application
pGM10	<i>HindIII</i> upstream of <i>ykoY</i> to <i>EcoRI</i> in <i>ykrM</i> , cloned into the <i>HindIII -EcoRI</i> sites of pBluescriptIIISK, Amp <sup>r</sup>	This application
pGM7H	<i>EcoRI</i> in <i>phaP</i> to <i>EcoRI</i> in <i>ykrM</i> , cloned into the <i>EcoRI</i> site of pHPS9, Cm <sup>r</sup>	This application
pC/GFP2	PhaC::GFP out-of-frame fusion plasmid. Fragment shown in Figure 4A cloned in pBluescriptIIISK, Amp <sup>r</sup>	This application
pC/GFP3	PhaC::GFP in-frame fusion plasmid.	This

pGM13	PhaC::GFP in-frame fusion plasmid. Fragment shown in Figure 4C cloned in pHPS9, Em <sup>r</sup> Lm <sup>r</sup>	This application
pGM13C	GFP localization control plasmid. Part of <i>phaB</i> and <i>phaC</i> deleted. Fragment shown in Figure 4D cloned in pHPS9, Em <sup>r</sup> Lm <sup>r</sup>	This application
pP/GFP3	PhaP::GFP in-frame fusion plasmid. Fragment shown in Figure 4E cloned in pBluescriptIIISK, Amp <sup>r</sup>	This application
pGM16.2	PhaP::GFP in-frame fusion plasmid. Fragment shown in Figure 4F cloned in pHPS9, Em <sup>r</sup> Lm <sup>r</sup>	This application
pGM107	<i>EcoRI</i> in <i>phaP</i> to <i>EcoRI</i> in <i>ykrM</i> , cloned as a <i>BamHI</i> - <i>SalI</i> fragment from pGM7, into the <i>BamHI</i> and <i>SalI</i> sites of pSUP104, Cm <sup>r</sup>	This application
pDR1	<i>PstI</i> in <i>phaB</i> to <i>EcoRI</i> in <i>ykrM</i> , cloned as a <i>SmaI</i> - <i>EcoRV</i> fragment from pGM6 into the two <i>DraI</i> sites of pSUP104 in same orientation as the Cm gene, with <i>phaC</i> expressed from the Cm promoter, Tc <sup>r</sup>	This application
pGM61	Derived from pGM13. It carries an in-frame 594 bp deletion in <i>phaR</i> , extending from 96 bp upstream of the <i>phaR</i> initiation codon through codon 144.	This Application
pGM73	Derived from pGM61. Carries a transcriptional fusion between the promoter of <i>phaP</i> and the coding region plus translation signals of <i>phaR</i> . A 663 bp DNA fragment harboring <i>phaR</i> was cloned into the <i>SnaBI</i> site in <i>phaP</i> in the sense orientation.	This Application

<sup>a</sup>Em<sup>r</sup>, erythromycin resistant; Lm<sup>r</sup>, lincomycin resistant; Cm<sup>r</sup>, chloramphenicol resistant; Amp<sup>r</sup>, ampicillin resistant; Tc<sup>r</sup>, Tetracycline resistant. <sup>b</sup>ATCC, American Type Culture Collection. <sup>c</sup>Origin of replication.

### Example 2: Media and growth conditions

Cultures were grown at 37°C (unless otherwise stated) in liquid media, aerated by rotation at 250 rpm in either Luria-Bertani (LB) broth (33) or M9 Minimal Salts (Life Technologies, Bethesda, MD) with 1% (w/v) glucose. For growth on plates, the above media with 1.5% agar (Sigma, A4550) was used. For plasmid selections, the appropriate antibiotics were included in the media: ampicillin (200 µg/mL [AMP<sup>200</sup>]), chloramphenicol (25 µg/mL [CM<sup>25</sup>]), erythromycin (200 µg/mL [EM<sup>200</sup>]), or tetracycline (12.5 µg/mL [TC<sup>12.5</sup>]) for plasmid selection in *Escherichia coli*; chloramphenicol (12 µg/mL [CM<sup>12</sup>]), or erythromycin (1 µg/mL [EM<sup>1</sup>]) plus lincomycin (25 µg/mL [LM<sup>25</sup>]) for plasmid selection in *Bacillus megaterium*; chloramphenicol (160 µg/mL [CM<sup>160</sup>]), or tetracycline (30 µg/mL [TC<sup>30</sup>]) for selection in *Pseudomonas*.

### Example 3: Transformations

*Escherichia coli* and *Pseudomonas putida* were transformed by electroporation of competent cells using an electroporator (Eppendorf) and following the manufacturers

instructions. *Bacillus megaterium* was transformed using a biolistic transformation procedure (39).

#### Example 4: Microscopy

For phase contrast microscopy, wet mounts of cultures were visualized at x1,000 magnification in a light microscope with phase contrast attachments (Labophot-2 Microscope, Nikon, Inc.). To view PHA inclusion-bodies, samples were heat fixed, stained with 1% (w/v) Nile Blue A (Sigma) for 15 minutes at 55°C, destained for 30 seconds in 8% (v/v) acetic acid, water washed, air dried, and viewed at x1000 magnification under fluorescence using filters; excitation, 446/10 nm; barrier filter, 590 nm; dichroic mirror, 580 nm. To view GFP, wet mounts of cultures with or without 1% (w/v) agarose were viewed at x1000 magnification under fluorescence using filters; excitation, 390-450 nm; barrier filter, 480-520 nm; dichroic mirror, 470 nm.

#### Example 5: Codon usage in *Bacillus megaterium*

*Bacillus megaterium* uses three codons as start codons in protein coding sequences. ATG, TTG, and GTG all encode methionine when present at the start of a coding region. TTG and GTG encode leucine and valine when present within a coding region, respectively. *Bacillus megaterium* uses TGA, TAA, and TAG as stop codons.

*Bacillus megaterium* sequences starting with TTG or GTG may require mutagenesis to ATG if the sequences are to be expressed in organisms that use ATG exclusively as a start codon.

#### Example 6: Separation of polypeptides associated with PHA inclusion-bodies.

In an attempt to determine their relevance, proteins that co-purify with PHA inclusion-bodies were separated by electrophoreses on an SDS-polyacrylamide gel (Figure 1).

Inclusion-bodies were purified (32) followed by suspension in TE buffer (10 mM Tris-HCl pH 8, 1 mM EDTA) with 2% (w/v) SDS. An equal volume of 2x sample buffer



### Example 7: Cloning the *pha* region

Purification of genomic and plasmid DNA, Southern blot, hybridization and cloning were by standard procedures (38). To clone the DNA sequences that coded for the two most abundant proteins on purified PHA inclusion-bodies, degenerate oligonucleotide probes based on their N-terminal amino acid sequences were used. The probes were: AAYACRGTNAAATAYNNNACRGTNATYNNNGCDATGATG (n2, SEQ ID NO:12) and GCDATYCCDTAYGTNCARGAAGGHTTYAAA (n5, SEQ ID NO:13) for the 20 kDa and 41 kDa proteins, respectively (Figure 1).

Both probes, used in separate 38°C Southern blotting hybridization experiments, identified a 6.4 kb HindIII, a 5.2 kb EcoRI, and a 3.7 kb HindIII to EcoRI DNA fragment of DNA, indicating that the 5' ends of the coding regions for both of these proteins were located less than 3.7 kb apart in the genome. The three fragments were purified from agarose following electrophoresis, and cloned into plasmid pBluescriptIISK.

Positive clones were identified by hybridization to the same degenerate probes, thus yielding plasmid pGM1 containing the 3.7 kb fragment. Sequences contiguous with and overlapping this primary cloned fragment were cloned in a similar manner except that probes based on the ends of the sequenced DNA fragment were used, and hybridization was performed at 55°C. The probes used were GCTTCATGCGTGCGGTTTG (bmp, SEQ ID NO:14) and GGACCGTTCGGAAAATCAGCGG (bmc, SEQ ID NO:15), yielding respectively, pGM9 and pGM6 (Figure 2).

DNA fragments of pGM1, pGM6 and pGM9 were subcloned into pBluescriptIISK, and sequenced, from both ends using universal primers and internally by primer walking on both strands, using dye terminator chemistry, cycle sequencing and an ABI Prism 377 sequencer (Applied Biosystems). Sequence assembly and analysis was performed using Lasergene (DNASTar, Inc.), and Gapped BLAST and PSI BLAST (1).

The 3.7 kb fragment contained 5 ORFs (Figure 2), whose predicted amino acid sequences encode PhaP (20 kDa protein), PhaQ, PhaR, PhaB and PhaC (41 kDa protein). The 20 and 41 -kDa proteins were identified by their N-terminal amino acid sequences.

Since the C-terminus for each of these two proteins extended beyond the boundaries of pGM1, the remaining sequence were obtained from plasmids pGM6 and pGM9.

#### Example 8: The *pha* locus.

The 7,916 bp region (SEQ ID NO:1) containing *pha* genes from *Bacillus megaterium* was cloned, sequenced and characterized. It was shown to carry 8 complete and 1 incomplete open reading frame (Figure 2, Tables 3 and 4). Coding sequences in this region were assigned on the basis of homology to known sequences, N-terminal amino acid sequences, putative ribosome binding sites and operon location. The complement and arrangement of genes flanking the *pha* genes in *Bacillus megaterium* are very similar to a region of *Bacillus subtilis* 168 (Figure 2). This strain is negative for PHA and no known *pha* genes or sequences occur in its genome, for which the complete sequence is available (24). In place of *pha* genes in this region of *B. subtilis* are *ykrI*, *ykrK* and *ykrL*, which, respectively, code for putative proteins similar to two unknown proteins, and a probable heat shock protein.

Table 3: Sequence analysis results

Sequence	Number of amino acids	Mol mass Daltons	Isoelectric point
<i>ykoY</i>	271	29,996	6.89
<i>ykoZ</i>	236	27,662	9.36
<i>sspD</i>	65	7,027	8.58
<i>phaP</i>	170	19,906	5.29
<i>phaQ</i>	146	16,686	5.09
<i>phaR</i>	168	19,150	5.10
<i>phaB</i>	247	26,098	7.39
<i>phaC</i>	362	41,463	8.31
<i>ykrM</i>	318 <sup>a</sup>	ND	ND

<sup>a</sup>Partial protein.

Table 4: Sequence homologies

Sequence	Homologies to known and putative genes (accession no.) <sup>a</sup>	Identity	Similarity	Function or putative function
<i>ykoY</i>	YkoY, <i>B. subtilis</i> (Z99110)	64%	73%	Toxic anion resistance protein (24)
<i>ykoZ</i>	YkoZ, <i>B. subtilis</i> (Z99111)	57%	74%	RNA polymerase sigma factor (24)
<i>sspD</i>	SspD, <i>Bacillus megaterium</i> (P10572)	100%		Spore specific, DNA binding protein (4, 10)
	SspD, <i>B. subtilis</i> (P04833)	73%	87%	
<i>phaP</i>	None			PHA inclusion-body structure, shape and size (49)
<i>phaQ</i>	None			Unknown
<i>phaR</i>	None			Unknown
<i>phaB</i>	FabG, <i>Synechocystis</i> (D90907)	50%	66%	Fatty acid biosynthesis (23)
	PhaB, <i>C. vinosum</i> D (P45375)	48%	64%	3-ketoacyl-CoA reductase (28)
	FabG, <i>B. subtilis</i> (P51831)	47%	67%	Fatty acid biosynthesis (35)
<i>phaC</i>	PhaC, <i>T. violacea</i> (P45366)	38%	59%	PHA synthase (29, 23, 28)
	PhaC, <i>Synechocystis</i> (D90906)	37%	56%	
	PhaC, <i>C. vinosum</i> (P45370)	35%	55%	
<i>ykrM</i>	YkrM, <i>B. subtilis</i> (Z99111)	55%	71%	Na <sup>+</sup> -transporting ATP synthase (24)

<sup>a</sup>Accession numbers are SWISS-PROT, EMBL or DDBJ; <sup>b</sup>None, No discernible similarity to known sequences.

#### Example 9: The *pha* nucleic acid and encoded protein sequences

The deduced amino acid sequence of PhaP shows a 20 kDa extremely hydrophilic product with no obvious similarity to known sequences (Figure 6). Inclusion-body associated low molecular weight proteins (phasins) have been described in many bacteria (49), but where sequences were available no similarities of identifiable significance with PhaP of *Bacillus megaterium* were found.

Low molecular weight, PHA inclusion-body abundant proteins play an important role in PHA producing cells, since they are involved in determining inclusion-body size and shape, and are present in quantities up to 5% of total protein in the case of PHA producing *A. eutrophus* (48). It is an interesting observation that the amino acid sequences of phasin proteins are so dissimilar, even in closely related bacteria. Some similarity between such proteins would be expected in closely related bacteria, were they to have a role in inclusion-body biogenesis, however, conservation of sequence would be entirely unnecessary should they have a role as storage proteins.



confirmed by the recloning of *phaR* into pGM61 (pGM73) as it was isolated from PHA05(pGM61) strain, followed by the introduction of pGM73 into PHA05. Accumulation of PHA in PHA05(pGM73) confirmed the preference for *phaR*. It has been previously demonstrated that the small type PhaCs (see Example 17) is not sufficient for PHA synthesis; another peptide, PhaE of approximate size 30 kDa, is also required (51). These complementation studies suggest that it is preferable to combine PhaC of *B. megaterium* (also a small type PhaC) and *phaR* (19 kDa), however there is no sequence similarity between *phaR* of *B. megaterium* and *phaE* of other organisms.

#### Example 11: Mapping transcription starts

The transcription start points were mapped in the region from the *EcoRI* restriction site in *phaP* to the *HindIII* site in *ykrM* by primer extension analysis, using the Promega system for primer extension on RNA templates. DNA oligonucleotide primers, 17 to 20 nucleotides in length, were synthesized to match target sequences, initially at approximately 500 base pair intervals and subsequently at about 50 to 250 nucleotides down-stream from the predicted transcription start points. The <sup>32</sup>P 5' end-labeled primers were extended with reverse transcriptase using total RNA (10 µg per reaction) purified from *Bacillus megaterium* (31). The fragment length initially, and transcription start nucleotides subsequently, were determined by running the cDNA on a 8% denaturing polyacrylamide gel along-side the products of sequencing reactions, which were generated using the same 5'-end labeled primers. The primers used to identify the transcription start nucleotides for the *phaP*, *phaQ*, and *phaRBC* promoters were, respectively, CCCCTTTGTCCATTGTTCCC (SEQ ID NO:16); CCATGTAGATTCCACCCTC (SEQ ID NO:17); and CTCCATCTCCTTCTTGTTG (SEQ ID NO:18).

Primer extension products showed a single band from each reaction, indicating one transcript, while control reactions in which RNA was omitted showed no bands. The extension products run alongside sequencing reaction products obtained with the same primer (Figure 2C), identified the 5' ends of the transcripts thus allowing the putative

promoter sequences at approximately -10 and -35 -bp for *phaP*, -*Q* and -*R* to be identified. The arrangement of genes in the *pha* cluster of *Bacillus megaterium* is unique among those already published and *phaA* is notably absent. The *phaP*, -*Q*, -*R*, -*B* and -*C* genes were shown to be in a 4,104 -bp region, with *phaP* and -*Q* transcribed in one orientation, each from a separate promoter, while *phaR*, -*B* and -*C* were divergently transcribed from a promoter in front of *phaR*. The putative promoters responsible for transcription of *phaQ* and *phaR*, *phaB* and *phaC* show strong similarity to both *Bacillus subtilis* Sigma A type (34) and *Escherichia coli*, Sigma 70 type promoters (14), which can express constitutively. This is in keeping with previous data for *Alcaligenes eutrophus* showing that *phaC* is constitutively synthesized, but PHA is not constitutively accumulated (19). The third putative promoter in this region, the *phaP* promoter, resembles a Sigma D (SigD) type promoter known to control the expression of a regulon of genes associated with flagellar assembly, chemotaxis and motility (13, 20, 46). In *Bacillus subtilis* Sigma D is expressed in the exponential phase and peaks in late exponential phase of growth. This parallels the pattern of PHA accumulation previously described for *Bacillus megaterium* 11561 (32). However, further experiments are required to test the hypothesis that PHA accumulation is regulated by sigma D or products of its resulting transcripts. The *phaP* gene has 18 -bp duplicate sequences that could base-pair to form a *rho*-independent terminator close to its translational stop codon (Figure 2B). The fact that the -35 promoter region of *sspD* is within this putative hairpin structure, suggests that transcription of *phaP* and *sspD* could be mutually exclusive, thus allowing the expression of *phaP* to play a regulatory role in the expression of *sspD* (spore specific storage protein).

#### Example 12: Expression of *Bacillus megaterium pha* genes in *Escherichia coli* and *Pseudomonas putida*

Functionality of the *Bacillus megaterium* putative *pha* gene cluster was tested in *Escherichia coli*, which is naturally PHA negative, and *Pseudomonas putida* GPp104, a *phaC*<sup>-</sup> mutant. Plasmids carrying one or more of these genes were introduced and the

resulting transformants were tested for PHA accumulation following growth on LB or M9 medium with various carbon sources and the appropriate antibiotic for plasmid selection.

5 Triplicate 500 mL cultures, were grown in 2 liter flasks at 30°C, rotating at 250, using 1% inocula of 16 hour cultures, which had been grown in LB, centrifuged and resuspended in equal volumes of 0.9% saline. At 48 hours samples were removed for microscopy and cells were harvested, washed once in dH<sub>2</sub>O and lyophilized. For PHA extraction, lyophilized cells were suspended in 10 volumes of 5% (w/v) bleach, shaken at 65°C for 1 hour and centrifuged. The pellet was resuspended in 10 volumes of 5% bleach and centrifuged followed by sequentially washing in water and 95% ethanol. The amount of PHA is expressed as percent PHA per mass of vacuum dried cells (w/w).

10 *Escherichia coli* carrying pGM7 or pGM10 accumulated low levels of PHA while *Escherichia coli* carrying pGM1 or pGM6 accumulated no PHA. Fluorescence microscopy of Nile Blue A stained cells showed approximately 1 cell in 20 had one or several inclusion-bodies and the quantity of PHA produced was approximately 5% of cell dry weight. Since *Escherichia coli* does not have PhaA, a low level or no PHA is the expected result. However, in *Pseudomonas* where PhaA is not known to be required, *Pseudomonas putida* GPp104 (pGM107) accumulated PHA on rich as well as minimal medium with various carbon sources to >50% of cell dry weight, and 90 to 100% of cells appeared full of PHA (Table 5). The positive control *P. oleovorans*, (equivalent to wild-type *Pseudomonas putida*) accumulated PHA only when grown on longer chain carbon sources, and not on LB. No PHA was accumulated by the negative control or by *Pseudomonas putida* carrying *phaC* alone (pDR1). These results showed that this *Bacillus megaterium* gene cluster is functional in both *Escherichia coli* and *Pseudomonas putida*. It is not known if the negative results obtained with pDR1 was due to PhaC alone being insufficient to complement PhaC<sup>-</sup> *Pseudomonas putida* or to synthesize PHA in *Escherichia coli*, or if the expression of *phaC* on pDR1 was not successful in producing protein.

Table 5: Cells with PHA as a percent<sup>1</sup> of total cells following growth on different carbon sources

Substrates (no. C atoms)	Source of genes:	Positive control:	Negative control, vector only:	<i>phaP<sup>n</sup>QRBC</i> :	<i>phaC</i> :
	<i>Bacillus megaterium</i>	<i>P. oleovorans</i>	<i>Pseudomonas putida</i> GPp104 (pSUP104)	<i>Pseudomonas putida</i> GPp104 (pGM107)	<i>Pseudomonas putida</i> GPp104 (pDR1)
LB	100	0	0	90	0
LB/Glucose, 1%	100	0	0	92	0
M9/Caproate, 12 mM (C6)	no growth	88	0	100*	0
M9/Octanoate, 12 mM (C8)	no growth	90	0	92	0

<sup>1</sup>100%, PHA in all cells; 0%, no PHA in any cell; data averaged from >5 fields of each of 3 different cultures, error less than 5%. <sup>n</sup>N-terminus only present. \* Cell shape distorted by large quantity of PHA.

These results suggest that the *B. megaterium* gene cluster, *phaP*, *-Q*, *-R*, *-B*, and *-C*, is functional in both *E. coli* and *P. putida* in so far as accumulation of PHA polymer. It is not known if the negative results obtained with pDR1 were due to PhaC alone being insufficient to complement the PhaC mutant of *P. putida* or to synthesize PHA in *E. coli*.

#### Example 13: Localization of PhaP and PhaC proteins

Proteins associated with purified PHA inclusion-bodies may not accurately reflect the localization of these proteins within the growing cell. Visualization of *pha::gfp* gene product fusion proteins in living cells throughout culture growth is a useful method for determining both the localization of the *pha* gene products and their comparative levels in growing cells. PhaP and PhaC, as fusion proteins (Figure 4), localized to PHA inclusion-bodies at all time points tested throughout growth of *Bacillus megaterium* 11561. The negative control (pHPS9) showed no fluorescence at any time point. The localization control (pGM13C) showed non-localized green fluorescence at all time points. The profiles of PHA accumulation in these two control strains were similar to that of the wild-type, where the quantity of PHA decreased during the lag phase, increased during exponential phase, and continued to increase at a lower steady state rate in stationary phase growth (32).

At time 0, cultures of *Bacillus megaterium* carrying, pGM16.2, pGM13, pGM13C or pHPS9, grown in LB with LM<sup>25</sup> EM<sup>1</sup> for 24 hours at 35°C, were inoculated (5% v/v) into 75 mL of fresh media of the same composition, in 300 mL Naphelco flasks, and growth was continued at 27°C, 250 rpm. Optical densities of cultures were monitored and samples were removed for microscopy at time points starting at time 0, for up to 24 hours. One part of each sample was immediately observed for green fluorescence by embedding in 1% low melting point agarose for viewing in phase contrast and under fluorescence for GFP, magnification x1000. Another part of each sample was stained for PHA and viewed under light microscopy and by fluorescence for PHA inclusion bodies, magnification x1000. Images were recorded using identical parameters for all samples to allow comparison of fluorescence and light intensities (f-stop, 1/15; brightness, 0.6; sharpness, 1.0; contrast, 0.8; color, 0.3; see also methods and materials). Results are shown in Figure 5 (A-F).

PhaP, monitored as a PhaP::GFP fusion protein in pGM16.2 (Figures 5A and 5B), decreased significantly during the first half (2 hours) of lag phase growth, increased during late lag phase and early to mid-exponential phase, decreased in mid to late exponential phase and increased during stationary phase growth. A possible explanation for the rapid decrease of PhaP in lag phase is that PhaP may be a storage protein that is degraded as a source of amino acids. The profile of PHA accumulation in these cells (carrying pGM16.2) followed a similar pattern to that of PhaP except that PHA decreased only in the lag phase and continued to accumulate throughout other phases of culture growth. This data is consistent with PHA inclusion-bodies being a source of carbon, reducing equivalents and amino acids when the organism is first provided with fresh medium. Possible explanations as to why the level of PhaP and not PHA decreased at mid to late exponential phase are that either PhaP was synthesized at a slower rate than that of PHA, or PhaP was used as a source of amino acids at this phase of growth or both scenarios may apply.

PhaC, monitored as a PhaC::GFP fusion protein in pGM13 showed a similar profile of expression to that of PhaP with one exception: PhaC did not reduce in level

during lag phase growth. It did, however, reduce in level in mid to late exponential phase growth, as did PhaP. The profile of PHA accumulation in these cells carrying PhaC::GFP was similar to that of cells carrying PhaP::GFP, except that the PHA level did not reduce during lag phase growth. The increased quantity of PhaC in the cell is a likely explanation since PhaC remained functional in the fusion protein PhaC::GFP. This was indicated by the fact that *Escherichia coli* DH5 $\alpha$  (pC/GFP3) and *Escherichia coli* DH5 $\alpha$  (pGM7) accumulated PHA to equivalent low levels, while the host strain alone, or carrying pGFPuv accumulated no PHA, as visualized by fluorescence microscopy of Nile Blue A stained cells. The reduction in level of PhaC in mid to late exponential phase, as was also seen with PhaP, is consistent with both PhaC and PhaP being synthesized at a slower rate than that of PHA.

In cells of all growth phases, inclusion-bodies were rarely visible under light in stained heat fixed cells while larger inclusion-bodies were visible in phase contrast of living cells (Figure 5C-F). In older cultures (2 days and older) some cells were lysed, and showed PhaP::GFP and PhaC::GFP localized to free PHA inclusion-bodies (Figure 5D). Both free and intracellular inclusion-bodies had doughnut shaped localization of GFP at some focal planes while at other focal planes the same inclusion-bodies appeared completely covered in GFP. We interpret this data as a difference in quantity of GFP that is visible when viewed through the edge or the center of the inclusion-bodies.

#### Example 14: Analysis of *Bacillus megaterium* 3-ketoacyl-CoA reductase PhaB

Stereospecificity assays were conducted on the *Bacillus megaterium* reductase using various chain length enoyl-CoA esters (C4-C8, Table 6). The assay was done using crotonase from Sigma (L-hydroxy acids) or hydratase from *Rhodospirillum rubrum* (D-hydroxy acids) to form the 3-hydroxyacyl-CoA compounds from the enoyl-CoA esters. Acetoacetyl-CoA reductase activity was monitored spectrophotometrically as the reduction of NADP<sup>+</sup> while 3-hydroxyacyl-CoAs were oxidized. Based on the assay results (Table 6) the *Bacillus megaterium* reductase is a D-specific enzyme with a

preference for C6 carbon chains. Enzyme reactions using NADH as electron donor for 3-ketoacyl-CoA reduction did not indicate significant enzyme activity with this cofactor.

Table 6: Analysis for stereo-specificity of the *Bacillus megaterium* 3-ketoacyl-CoA reductase.

Clone # <sup>a</sup>	D-stereoisomer (hydratase)	Spec. act. U/mg		Clone #	L-stereoisomer (crotonase)	Spec. act. U/mg
B1-30	Crotonyl CoA	0.155		B1-30	Crotonyl CoA	0.014
B1-30	C5	0.15		B1-30	C5	0.009
B1-30	C6	0.39		B1-30	C6	0.017
B1-30	C6	0.014		B1-30	C6	0.039
B5-20	Crotonyl CoA	0.077		B5-20	Crotonyl CoA	0.004
B5-20	C5	0.074		B5-20	C5	0.01
B5-20	C6	0.219		B5-20	C6	0.012
B5-20	C8	0.003		B5-20	C8	0.001
Negative	Crotonyl CoA	0.02		Negative	Crotonyl CoA	0.001
Negative	C5	0.011		Negative	C5	0.003
Negative	C6	0.006		Negative	C6	0.008
Negative	C8	0.033		Negative	C8	0.003

<sup>a</sup> Clone B1-30 contains pMON48213; clone B5-20 contains pMON48214.

#### Example 15: Verification of the *Bacillus megaterium* 3-ketoacyl-CoA reductase for PHA accumulation

The functionality of the *Bacillus megaterium* sequence for PHA accumulation in a recombinant system was assayed. *Escherichia coli* DH5 $\alpha$  harboring either pMON48222 (*phaA*<sub>Re</sub>, *phaB*<sub>Bm</sub>, *phaC*<sub>Re</sub>) only, or two of the following plasmids: pJM9238  $\Delta$ AB (*phaA* and *phaB* deleted by *FseI* digest and religation) or pJM9117  $\Delta$ AB (*phaA* and *phaB* deleted by *FseI* digest and religation) and pMON48220 (*phaA*<sub>Re</sub>, *phaB*<sub>Bm</sub>) was grown in LB + mannitol in concentrations of 1 or 2 % (w/v), respectively. Cultures were induced for PHA accumulation at OD<sub>600</sub> = 0.6. Percentage PHA (Table 7) and enzyme activity (Table 8) were determined. Plasmid pMON48213 contains the same *pha* sequences as pMON48220, but was constructed with pSE380 (Invitrogen, Carlsbad, CA), a high level

expression vector. Plasmid pMON48221 contains the same pha sequences as pMON48220, but lacks a small fragment of the multicloning site between *phaA<sub>Re</sub>* and *phaB<sub>Bm</sub>*.

3-Ketoacyl-CoA reductase was monitored in a total volume of 1 mL containing  
 5 100 mM potassium phosphate buffer pH 7.0, 50  $\mu$ M acetoacetyl-CoA and 150  $\mu$ M NADPH. The reaction mixture contained between 5 and 50  $\mu$ L cell extract. Assays were monitored spectrophotometrically at 340 nm.

Table 7: Application of the *Bacillus megaterium* 3-ketoacyl-CoA reductase for PHA formation in *Escherichia coli*

Vectors			% PHA	Standard deviation
pMON48222-4			12.9	
pMON48222-8			19.2	
		Average	16.1	$\pm 4.5$
pJM9238 $\Delta$ AB	pMON48220		23.7	
pJM9238 $\Delta$ AB	pMON48220		18.9	
		Average	21.3	$\pm 3.4$
pJM9238 $\Delta$ AB		Average	1.5	$\pm 1.5$
pJM9117 $\Delta$ AB	pMON48220		12.5	
pJM9117 $\Delta$ AB	pMON48220		3.9	
		Average	8.2	$\pm 6.1$
pJM9117 $\Delta$ AB		Average	0.7	$\pm 0.1$

Table 8: Enzyme activity of the *Bacillus megaterium* 3-ketoacyl-CoA reductase using pMON48220 and pMON48213

Vector	acetoacetyl-CoA reductase[U/mg]
Negative control	0.08
pMON48220-2	0.24
	0.15
pMON48220-9	0.22
	0.23
Average	0.21 ± 0.04
pMON48213	4.0

Table 9: Verification of the *Bacillus megaterium* 3-ketoacyl-CoA reductase functionality

<i>E. coli</i> DH5α containing plasmids	Relevant genotype	PHB content % CDW
pJM9238ΔAB, pMON34610	<i>phaC<sub>Re</sub></i>	nd
pJM9238ΔAB, pMON34575	<i>phaC<sub>Re</sub>, phaA<sub>Re</sub></i>	1.2 ± 0.4
pJM9238ΔAB, pMON48221	<i>phaC<sub>Re</sub>, phaA<sub>Re</sub>, phaB<sub>Bm</sub></i>	22.2 ± 4.7

nd = not detectable

#### Example 16: Additional sequences in genomic fragment

The 7,916 base pair genomic fragment (SEQ ID NO:1) additionally contained three complete open reading frames and one incomplete open reading frame encoding proteins in addition to PhaP, PhaQ, PhaR, PhaB, and PhaC. As indicated in Tables 3 and 4, sequence comparisons suggest that *ykoY* (SEQ ID NO:22) encodes toxic anion resistance protein YkoY (SEQ ID NO:23), *ykoZ* (SEQ ID NO:24) encodes RNA polymerase sigma factor protein YkoZ (SEQ ID NO:25), and *ykrM* (SEQ ID NO:26) encodes a portion of the Na<sup>+</sup>-transporting ATP synthase protein YkrM (SEQ ID NO:27). Sequence *sspD* (SEQ ID NO:28) matches the known *Bacillus megaterium* sequence (4, 10) encoding SspD (SEQ ID NO:29). While the activity of the proteins is identified by their similarity to other known proteins, it is possible that the proteins may have additional functionality involved in polyhydroxyalkanoate biosynthesis.

These nucleic acid and amino acid sequences may be used in nucleic acid segments, recombinant vectors, transgenic host cells, and transgenic plants.

Example 17: One and two subunit PHA synthase proteins

- PHA synthases have been identified to be either one or two subunit enzymes (51).  
 5 Single subunit enzymes have only the PhaC protein, while two subunit enzymes have PhaC and PhaE protein subunits. Nucleic acid sequences encoding PhaE subunits have been found to be located adjacent to the nucleic acid sequences encoding PhaC.

Table 10: One and two subunit PHA synthases

Source organism (Reference)	Subunits	PhaC Amino acids
<i>T. violacea</i> (P45366, D48376)	2	355
<i>C. vinosum</i> (P45370, S29274)	2	355
<i>T. pfennigii</i> (WO 96/08566)	2	357
<i>Synechocystis</i> sp. PCC6803 (50, D90906, S77327)	2	378
<i>P. oleovorans</i> (22, A38604)	1	559
<i>P. aeruginosa</i> (S29305)	1	559
<i>R. ruber</i> (S25725)	1	562
<i>R. eutropha</i> (A34371)	1	589
<i>A. caviae</i> (D88825)	1	594
<i>P. denitrificans</i> (JC6023)	1	624
<i>R. etli</i> (3, U30612)	1	636
<i>B. megaterium</i> (SEQ ID NO:11)		362

- Based on the number of amino acids in the deduced sequence and homology to  
 10 known PhaC proteins, the *B. megaterium* would be expected to be part of a two subunit synthase. However, the nucleic acid sequences adjacent to *phaC* in the 7,916 base pair genomic fragment show no significant similarity to a *phaE* sequence. Upstream of *phaC* is *phaB*, and downstream is *ykrM*, a suspected Na<sup>+</sup> transporting ATP synthase (Table 4).  
 In combination with the observation that the *B. megaterium* sequences were able to  
 15 complement *P. putida* GPp104 to accumulate PHA, this suggests that the *B. megaterium*

phaC may encode a novel class of PHA synthase, i.e. a single subunit synthase with a molecular weight in the range of two subunit PhaC proteins.

#### Example 18: Pathway for the production of C4/C6/C8/C10 PHA copolymers

Figure 10 outlines a proposed biosynthetic pathway for the production of PHA copolymers incorporating C4 and/or C6 monomer units. Produced polymers may include C4-co-C6, C4-co-C8, C4-co-C6-co-C8, C6-co-C8, C6, and C8. A recombinant host cell or plant may be constructed to contain the nucleic acid sequences encoding the required enzymes.

The  $\beta$ -ketothiolase is preferably BktB (53, WO 98/00557). The  $\beta$ -ketothiolase can condense two molecules of acetyl-CoA to form acetoacetyl-CoA. This product may be reduced to 3HB-CoA by the *Bacillus megaterium* 3-keto-acyl-CoA reductase protein. 3HB-CoA may be converted to crotonyl-CoA by a hydratase such as that from *Aeromonas caviae* (54). Subsequent reduction to butyryl-CoA is performed by a butyryl-CoA dehydrogenase such as that cloned from *Clostridium acetobutylicum* (55). This product may be condensed with acetyl-CoA by the  $\beta$ -ketothiolase to afford 3-ketohexanoyl-CoA. This is the preferred substrate of the *Bacillus megaterium* reductase, leading to the production of 3-hydroxyhexanoyl-CoA. This product may be incorporated into C6 polymers or copolymers (e.g. C4-co-C6) by a PHA synthase having a broad substrate specificity (e.g. (56)). An additional round of condensation may lead to production of the C8 monomer, allowing the introduction of C8 into PHA polymers or copolymers. A further additional round of condensation may lead to production of the C10 monomer, allowing the introduction of C10 into PHA polymers or copolymers.

#### Example 19: Nucleic acid mutation and hybridization

Variations in the nucleic acid sequence encoding a protein may lead to mutant protein sequences that display equivalent or superior enzymatic characteristics when compared to the sequences disclosed herein. This invention accordingly encompasses nucleic acid sequences which are similar to the sequences disclosed herein, protein

sequences which are similar to the sequences disclosed herein, and the nucleic acid sequences that encode them. Mutations may include deletions, insertions, truncations, substitutions, fusions, shuffling of subunit sequences, and the like.

Mutations to a nucleic acid sequence may be introduced in either a specific or random manner, both of which are well known to those of skill in the art of molecular biology. A myriad of site-directed mutagenesis techniques exist, typically using oligonucleotides to introduce mutations at specific locations in a nucleic acid sequence. Examples include single strand rescue (Kunkel, T. *Proc. Natl. Acad. Sci. U.S.A.*, 82: 488-492, 1985), unique site elimination (Deng and Nickloff, *Anal. Biochem.* 200: 81, 1992), nick protection (Vandeyar, et al. *Gene* 65: 129-133, 1988), and PCR (Costa, et al. *Methods Mol. Biol.* 57: 31-44, 1996). Random or non-specific mutations may be generated by chemical agents (for a general review, see Singer and Kusmierek, *Ann. Rev. Biochem.* 52: 655-693, 1982) such as nitrosoguanidine (Cerdeira-Olmedo et al., *J. Mol. Biol.* 33: 705-719, 1968; Guerola, et al. *Nature New Biol.* 230: 122-125, 1971) and 2-aminopurine (Rogan and Bessman, *J. Bacteriol.* 103: 622-633, 1970), or by biological methods such as passage through mutator strains (Greener et al. *Mol. Biotechnol.* 7: 189-195, 1997).

Nucleic acid hybridization is a technique well known to those of skill in the art of DNA manipulation. The hybridization properties of a given pair of nucleic acids is an indication of their similarity or identity. Mutated nucleic acid sequences may be selected for their similarity to the disclosed nucleic acid sequences on the basis of their hybridization to the disclosed sequences. Low stringency conditions may be used to select sequences with multiple mutations. One may wish to employ conditions such as about 0.15 M to about 0.9 M sodium chloride, at temperatures ranging from about 20°C to about 55°C. High stringency conditions may be used to select for nucleic acid sequences with higher degrees of identity to the disclosed sequences. Conditions employed may include about 0.02 M to about 0.15 M sodium chloride, about 0.5% to about 5% casein, about 0.02% SDS and/or about 0.1% N-laurylsarcosine, about 0.001 M to about 0.03 M sodium citrate, at temperatures between about 50°C and about 70°C.

More preferably, high stringency conditions are 0.02 M sodium chloride, 0.5% casein, 0.02% SDS, 0.001 M sodium citrate, at a temperature of 50°C.

#### Example 20: Determination of homologous and degenerate nucleic acid sequences

Modification and changes may be made in the sequence of the proteins of the present invention and the nucleic acid segments which encode them and still obtain a functional molecule that encodes a protein with desirable properties. The following is a discussion based upon changing the amino acid sequence of a protein to create an equivalent, or possibly an improved, second-generation molecule. The amino acid changes may be achieved by changing the codons of the nucleic acid sequence, according to the codons given in Table 11.

Table 11: Codon degeneracies of amino acids

Amino acid	One letter	Three letter	Codons
Alanine	A	Ala	GCA GCC GCG GCT
Cysteine	C	Cys	TGC TGT
Aspartic acid	D	Asp	GAC GAT
Glutamic acid	E	Glu	GAA GAG
Phenylalanine	F	Phe	TTC TTT
Glycine	G	Gly	GGA GGC GGG GGT
Histidine	H	His	CAC CAT
Isoleucine	I	Ile	ATA ATC ATT
Lysine	K	Lys	AAA AAG
Leucine	L	Leu	TTA TTG CTA CTC CTG CTT
Methionine	M	Met	ATG
Asparagine	N	Asn	AAC AAT
Proline	P	Pro	CCA CCC CCG CCT
Glutamine	Q	Gln	CAA CAG
Arginine	R	Arg	AGA AGG CGA CGC CGG CGT
Serine	S	Ser	AGC AGT TCA TCC TCG TCT
Threonine	T	Thr	ACA ACC ACG ACT
Valine	V	Val	GTA GTC GTG GTT
Tryptophan	W	Trp	TGG
Tyrosine	Y	Tyr	TAC TAT

Certain amino acids may be substituted for other amino acids in a protein sequence without appreciable loss of enzymatic activity. It is thus contemplated that various changes may be made in the peptide sequences of the disclosed protein sequences, or their corresponding nucleic acid sequences without appreciable loss of the biological activity.

In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, *J. Mol. Biol.*, 157: 105-132, 1982). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics. These are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate/glutamine/aspartate/asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, i.e., still obtain a biologically functional protein. In making such changes, the substitution of amino acids whose hydropathic indices are within  $\pm 2$  is preferred, those within  $\pm 1$  are more preferred, and those within  $\pm 0.5$  are most preferred.

It is also understood in the art that the substitution of like amino acids may be made effectively on the basis of hydrophilicity. U.S. Patent No. 4,554,101 (Hopp, T.P., issued November 19, 1985) states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. The following hydrophilicity values have been assigned to amino acids: arginine/lysine (+3.0); aspartate/glutamate (+3.0  $\pm 1$ ); serine

(+0.3); asparagine/glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5  $\pm$ 1); alanine/histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine/isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); and tryptophan (-3.4).

It is understood that an amino acid may be substituted by another amino acid having a similar hydrophilicity score and still result in a protein with similar biological activity, i.e., still obtain a biologically functional protein. In making such changes, the substitution of amino acids whose hydropathic indices are within  $\pm 2$  is preferred, those within  $\pm 1$  are more preferred, and those within  $\pm 0.5$  are most preferred.

As outlined above, amino acid substitutions are therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine, and isoleucine. Changes which are not expected to be advantageous may also be used if these resulted in functional fusion proteins.

#### Plant Vectors

In plants, transformation vectors capable of introducing nucleic acid sequences encoding polyhydroxyalkanoate biosynthesis enzymes are easily designed, and generally contain one or more nucleic acid coding sequences of interest under the transcriptional control of 5' and 3' regulatory sequences. Such vectors generally comprise, operatively linked in sequence in the 5' to 3' direction, a promoter sequence that directs the transcription of a downstream heterologous structural nucleic acid sequence in a plant; optionally, a 5' non-translated leader sequence; a nucleic acid sequence that encodes a protein of interest; and a 3' non-translated region that encodes a polyadenylation signal which functions in plant cells to cause the termination of transcription and the addition of polyadenylate nucleotides to the 3' end of the mRNA encoding the protein. Plant transformation vectors also generally contain a selectable marker. Typical 5'-3' regulatory sequences include a transcription initiation start site, a ribosome binding site,

an RNA processing signal, a transcription termination site, and/or a polyadenylation signal. Vectors for plant transformation have been reviewed in Rodriguez et al. (Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston., 1988), Glick et al. (Methods in Plant Molecular Biology and Biotechnology, CRC Press, Boca Raton, Fla., 1993), and Croy (Plant Molecular Biology Labfax, Hames and Rickwood (Eds.), BIOS Scientific Publishers Limited, Oxford, UK., 1993).

### Plant Promoters

Plant promoter sequences can be constitutive or inducible, environmentally- or developmentally-regulated, or cell- or tissue-specific. Often-used constitutive promoters include the CaMV 35S promoter (Odell, J.T. et al., *Nature* 313: 810-812, 1985), the enhanced CaMV 35S promoter, the Figwort Mosaic Virus (FMV) promoter (Richins et al., *Nucleic Acids Res.* 20: 8451-8466, 1987), the mannopine synthase (*mas*) promoter, the nopaline synthase (*nos*) promoter, and the octopine synthase (*ocs*) promoter. Useful inducible promoters include promoters induced by salicylic acid or polyacrylic acids (PR-1, Williams, S. W. et al., *Biotechnology* 10: 540-543, 1992), induced by application of safeners (substituted benzenesulfonamide herbicides, Hershey, H.P. and Stoner, T.D., *Plant Mol. Biol.* 17: 679-690, 1991), heat-shock promoters (Ou-Lee et al., *Proc. Natl. Acad. Sci U.S.A.* 83: 6815-6819, 1986; Ainley et al., *Plant Mol. Biol.* 14: 949-967, 1990), a nitrate-inducible promoter derived from the spinach nitrite reductase gene (Back et al., *Plant Mol. Biol.* 17: 9-18, 1991), hormone-inducible promoters (Yamaguchi-Shinozaki, K. et al., *Plant Mol. Biol.* 15: 905-912, 1990; Kares et al., *Plant Mol. Biol.* 15: 225-236, 1990), and light-inducible promoters associated with the small subunit of RuBP carboxylase and LHCP gene families (Kuhlemeier et al., *Plant Cell* 1: 471, 1989; Feinbaum, R.L. et al., *Mol. Gen. Genet.* 226: 449-456, 1991; Weisshaar, B. et al., *EMBO J.* 10: 1777-1786, 1991; Lam, E. and Chua, N.H., *J. Biol. Chem.* 266: 17131-17135, 1990; Castresana, C. et al., *EMBO J.* 7: 1929-1936, 1988; Schulze-Lefert et al., *EMBO J.* 8: 651, 1989). Examples of useful tissue-specific, developmentally-regulated promoters include the  $\beta$ -conglycinin 7S promoter (Doyle, J.J. et al., *J. Biol. Chem.* 261: 9228-9238,

1986; Slighton and Beachy, *Planta* 172: 356-363, 1987), and seed-specific promoters (Knutzon, D.S. et al., *Proc. Natl. Acad. Sci U.S.A.* 89: 2624-2628, 1992; Bustos, M.M. et al., *EMBO J.* 10: 1469-1479, 1991; Lam and Chua, *Science* 248: 471, 1991; Stayton et al., *Aust. J. Plant. Physiol.* 18: 507, 1991). Plant functional promoters useful for preferential expression in seed plastids include those from plant storage protein genes and from genes involved in fatty acid biosynthesis in oilseeds. Examples of such promoters include the 5' regulatory regions from such genes as napin (Kridl et al., *Seed Sci. Res.* 1: 209-219, 1991), phaseolin, zein, soybean trypsin inhibitor, ACP, stearyl-ACP desaturase, and oleosin. Seed-specific gene regulation is discussed in EP 0 255 378. Promoter hybrids can also be constructed to enhance transcriptional activity (Comai, L. and Moran, P.M., U.S. Patent No. 5,106,739, issued April 21, 1992), or to combine desired transcriptional activity and tissue specificity. A developing seed selective promoter may be obtained from the fatty acid hydroxylase gene of *Lesquerella* (P-lh) (Broun, P. and C. Somerville. *Plant Physiol.* 113: 933-942, 1997).

#### Plant transformation and regeneration

A variety of different methods can be employed to introduce such vectors into plant protoplasts, cells, callus tissue, leaf discs, meristems, etcetera, to generate transgenic plants, including *Agrobacterium*-mediated transformation, particle gun delivery, microinjection, electroporation, polyethylene glycolmediated protoplast transformation, liposome-mediated transformation, etcetera (reviewed in Potrykus, I. *Ann. Rev. Plant Physiol. Plant Mol. Biol.* 42: 205-225, 1991). In general, transgenic plants comprising cells containing and expressing DNAs encoding polyhydroxyalkanoate biosynthesis proteins can be produced by transforming plant cells with a DNA construct as described above via any of the foregoing methods; selecting plant cells that have been transformed on a selective medium; regenerating plant cells that have been transformed to produce differentiated plants; and selecting a transformed plant which expresses the protein-encoding nucleotide sequence.

Specific methods for transforming a wide variety of dicots and obtaining transgenic plants are well documented in the literature (Gasser and Fraley, *Science* 244: 1293-1299, 1989; Fisk and Dandekar, *Scientia Horticulturae* 55: 5-36, 1993; Christou, *Agro Food Industry Hi Tech*, p.17, 1994; and the references cited therein).

Successful transformation and plant regeneration have been reported in the monocots as follows: asparagus (*Asparagus officinalis*; Bytebier et al., *Proc. Natl. Acad. Sci. U.S.A.* 84: 5345-5349, 1987); barley (*Hordeum vulgare*; Wan and Lemaux, *Plant Physiol.* 104: 37-48, 1994); maize (*Zea mays*; Rhodes, C.A. et al., *Science* 240: 204-207, 1988; Gordon-Kamm et al., *Plant Cell* 2: 603-618, 1990; Fromm, M.E. et al., *Bio/Technology* 8: 833-839, 1990; Kozziel et al., *Bio/Technology* 11: 194-200, 1993); oats (*Avena sativa*; Somers et al., *Bio/Technology* 10: 1589-1594, 1992); orchardgrass (*Dactylis glomerata*; Horn et al., *Plant Cell Rep.* 7: 469-472, 1988); rice (*Oryza sativa*, including indica and japonica varieties; Toriyama et al., *Bio/Technology* 6: 10, 1988; Zhang et al., *Plant Cell Rep.* 7: 379-384, 1988; Luo and Wu, *Plant Mol. Biol. Rep.* 6: 165-174, 1988; Zhang and Wu, *Theor. Appl. Genet.* 76: 835-840, 1988; Christou et al., *Bio/Technology* 9: 957-962, 1991); rye (*Secale cereale*; De la Pena et al., *Nature* 325: 274-276, 1987); sorghum (*Sorghum bicolor*; Casas, A.M. et al., *Proc. Natl. Acad. Sci. U.S.A.* 90: 11212-11216, 1993); sugar cane (*Saccharum* spp.; Bower and Birch, *Plant J.* 2: 409-416, 1992); tall fescue (*Festuca arundinacea*; Wang, Z.Y. et al., *Bio/Technology* 10: 691-696, 1992); turfgrass (*Agrostis palustris*; Zhong et al., *Plant Cell Rep.* 13: 1-6, 1993); wheat (*Triticum aestivum*; Vasil et al., *Bio/Technology* 10: 667-674, 1992; Weeks, T. et al., *Plant Physiol.* 102: 1077-1084, 1993; Becker et al., *Plant J.* 5: 299-307, 1994), and alfalfa (Masoud, S.A. et al., *Transgen. Res.* 5: 313, 1996).

### Host plants

Particularly useful plants for polyhydroxyalkanoate production include those that produce carbon substrates, including tobacco, wheat, potato, *Arabidopsis*, and high oil seed plants such as corn, soybean, canola, oil seed rape, sugarbeet, sunflower, flax, peanut, sugarcane, switchgrass, and alfalfa.

### Example 21: Plastid transformation

Alternatively, polyhydroxyalkanoate biosynthesis enzymes facilitating the increase in oil content of plants and/or herbicide resistance discussed herein can be expressed in situ in plastids by direct transformation of these organelles with appropriate recombinant expression constructs. Constructs and methods for stably transforming plastids of higher plants are well known in the art (Svab, Z. et al., *Plant Mol. Biol.* 14(2): 197-205, 1990; Svab et al., *Proc. Natl. Acad. Sci. U S A.* 90(3): 913-917, 1993; Staub et al., *EMBO J.* 12(2): 601-606, 1993; Maliga et al., U.S. Patent No. 5,451,513; PCT International Publications WO 95/16783, WO 95/24492, and WO 95/24493). These methods generally rely on particle gun delivery of DNA containing a selectable or scorable marker in addition to introduced DNA sequences for expression, and targeting of the DNA to the plastid genome through homologous recombination. Transformation of a wide variety of different monocots and dicots by particle gun bombardment is routine in the art (Hinchee et al., 1994; Walden and Wingender, 1995). The plastid may be transformed by using protoplast and PEG (polyethylene glycol) (Koop, et al., *Physiol. Plant.* 85: 339, 1992; Golds et al., *Bio/Technol.* 11: 95-97, 1993), cocultivation of protoplasts and *Agrobacteria* carrying transformation vectors (De Block et al., *EMBO J.* 4: 1367-1372, 1985), and by electroporation (Kin-Ying et al., *Plant J.* 4: 737, 1996).

Nucleic acid constructs for plastid transformation generally comprise a targeting segment comprising flanking nucleic acid sequences substantially homologous to a predetermined sequence of a plastid genome, which targeting segment enables insertion of nucleic acid coding sequences of interest into the plastid genome by homologous recombination with the predetermined sequence; a selectable marker sequence, such as a sequence encoding a form of plastid 16S ribosomal RNA that is resistant to spectinomycin or streptomycin, or that encodes a protein which inactivates spectinomycin or streptomycin (such as the *aadA* gene), disposed within the targeting segment, wherein the selectable marker sequence confers a selectable phenotype upon plant cells, substantially all the plastids of which have been transformed with the nucleic acid construct; and one or more nucleic acid coding sequences of interest disposed within the

targeting segment relative to the selectable marker sequence so as not to interfere with conferring of the selectable phenotype. In addition, plastid expression constructs also generally include a plastid promoter region and a transcription termination region capable of terminating transcription in a plant plastid, wherein the regions are operatively linked to the nucleic acid coding sequences of interest.

A further refinement in chloroplast transformation/expression technology that facilitates control over the timing and tissue pattern of expression of introduced nucleic acid coding sequences in plant plastid genomes has been described in PCT International Publication WO 95/16783. This method involves the introduction into plant cells of constructs for nuclear transformation that provide for the expression of a viral single subunit RNA polymerase and targeting of this polymerase into the plastids via fusion to a plastid transit peptide. Transformation of plastids with nucleic acid constructs comprising a viral single subunit RNA polymerase-specific promoter specific to the RNA polymerase expressed from the nuclear expression constructs operably linked to nucleic acid coding sequences of interest permits control of the plastid expression constructs in a tissue and/or developmental specific manner in plants comprising both the nuclear polymerase construct and the plastid expression constructs. Expression of the nuclear RNA polymerase coding sequence can be placed under the control of either a constitutive promoter, or a tissue- or developmental stage-specific promoter, thereby extending this control to the plastid expression construct responsive to the plastid-targeted, nuclear-encoded viral RNA polymerase. The introduced nucleic acid coding sequence can be a single encoding region, or may contain a number of consecutive encoding sequences to be expressed as an engineered or synthetic operon. The latter is especially attractive where, as in the present invention, it is desired to introduce multigene biochemical pathways into plastids. This approach is more complex using standard nuclear transformation techniques since each gene introduced therein must be engineered as a monocistron, including an encoded transit peptide and appropriate promoter and terminator signals. Individual gene expression levels may vary widely among different

cistrons, thereby possibly adversely affecting the overall biosynthetic process. This can be avoided by the chloroplast transformation approach.

All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention.

## REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

1. Altschul, S.F., T.L. Madden, A.A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D.J. Lipman. 1997. Gapped BLAST and PSI BLAST: a new generation of protein database search programs. *Nucleic Acids Res.*, 25: 3389-3402.
2. Anderson, A. and E.A. Dawes. 1990. Occurrence, metabolism, metabolic role, and industrial uses of bacterial polyhydroxyalkanoates. *Microbiol. Rev.*, 54: 450-472.
3. Cevallos, M.A., S. Encarnacion, A. Leija, Y. Mora, and J. Mora. 1996. Genetic and physiological characterization of a *Rhizobium etli* mutant strain unable to synthesize poly-beta-hydroxybutyrate. *J. Bacteriol.*, 178: 1646-1654.
4. Connors, M.J., J.M. Mason, and P. Setlow. 1986. Cloning and nucleotide sequencing of genes for three small, acid soluble proteins *Bacillus subtilis* spores. *J. Bacteriol.*, 166: 417-425.
5. deSmet, M.J., G. Eggink, B. Witholt, J. Kingma, and H. Wynberg. 1983. Characterization of intracellular inclusions formed by *Pseudomonas oleovorans* during growth on octane. *J. Bacteriol.*, 154: 870-878.
6. Dunlop, W. and A.W. Robards. 1973. Ultrastructural study of poly- $\beta$ -hydroxybutyrate granules from *Bacillus cereus*. *J. Bacteriol.*, 114: 1271-1280.

7. Eggink, G., P. de Waard, and G.N.M. Huijberts. 1992. The role of fatty acid biosynthesis and degradation in the supply of substrates for poly(3-hydroxyalkanoate) formation in *Pseudomonas putida*. *FEMS Microbiol. Rev.*, 103: 159-164.
8. Ellar, D., D.G. Lundgren, K. Okamura, and R.H. Marchessault. 1968. Morphology of poly- $\beta$ -hydroxybutyrate granules. *J. Mol. Biol.*, 35: 489-502.
9. Fliss, E.R., A.C. Loshon, and P. Setlow. 1986. Genes for *Bacillus megaterium* small, acid-soluble spore proteins: Cloning and nucleotide sequence of three additional genes from this multigene family. *J. Bacteriol.*, 165: 467-473.
10. Fliss, E.R. and P. Setlow. 1984. *Bacillus megaterium* spore protein C-3: nucleotide sequence of its gene and the amino acid sequence at its spore cleavage site. *Gene*, 30: 167-172.
11. Fuller, R.C., J.P. O'Donnell, J. Saulnier, T.E. Redlinger, J. Foster, and R.W. Lenz. 1992. The supramolecular architecture of the polyhydroxyalkanoate inclusions in *Pseudomonas oleovorans*. *FEMS Microbiol. Rev.*, 103: 279-288.
12. Gerngross, T.U., P. Reilly, J. Stubbe, A.J. Sinskey, and O.P. Peoples. 1993. Immunocytochemical analysis of poly- $\beta$ -hydroxybutyrate (PHB) synthase enzyme at the surface of PHB granules. *J. Bacteriol.*, 175: 5289-5293.
13. Gilman, M.Z., J.L. Wings, and M.J. Chamberlin. 1981. Nucleotide sequence of two *Bacillus subtilis* promoters used by *Bacillus subtilis* sigma-28 RNA polymerase. *Nucleic Acids Res.*, 9: 5991-6000.

14. Gitt, M.A., L.F. Wang, and R.H. Doi. 1985. A strong sequence homology exists between RNA polymerase sigma factors of *Bacillus subtilis* and *Escherichia coli*. *J. Biol. Chem.*, 260: 7178-7185.
15. Griebel, R., Z. Smith, and M. Merrick. 1968. Metabolism of poly- $\beta$ -hydroxybutyrate. 1. Purification, composition, and properties of native poly- $\beta$ -hydroxybutyrate granules from *Bacillus megaterium*. *Biochem.*, 7: 3676-3681.
16. Haima, P., D. van Sinderen, H. Scholting, S. Bron, and G. Venema. 1990. Development of  $\beta$ -galactosidase  $\alpha$ -complementation system for molecular cloning in *Bacillus subtilis*. *Gene*, 86: 63-69.
17. Haywood, G.W., A.J. Anderson, L. Chu, and E.A. Dawes. 1988. The role of NADH- and NADPH-linked acetoacetyl-CoA reductases in the poly-3-hydroxybutyrate synthesizing organism *Alcaligenes eutrophus*. *FEMS Microbiol. Lett.*, 52: 259-264.
18. Haywood, G.W., A.J. Anderson, L. Chu, and E.A. Dawes. 1988. Characterization of two 3-ketothiolases in the polyhydroxyalkanoate synthesizing organism *Alcaligenes eutrophus*. *FEMS Microbiol. Lett.*, 52: 91-96.
19. Haywood, G.W., A.J. Anderson, and E.A. Dawes. 1989. The importance of PHB-synthase substrate specificity in polyhydroxyalkanoate synthesis by *Alcaligenes eutrophus*. *FEMS Microbiol. Lett.*, 57: 1-6.
20. Helmann, J.D. 1991. Alternative sigma factors and the regulation of flagellar gene expression. *Mol. Microbiol.*, 5: 2875-2882.

21. Huang, A.H.C. 1992. Oil bodies and oleosins in seeds. *Annu. Rev. Plant Physiol. Plant Mol. Biol.*, 43: 177-200.
22. Huisman, G.W., E. Wonink, R. Meima, B. Kazemier, P. Terpstra, and B. Witholt. 1991. Metabolism of poly(3-hydroxyalkanoates) (PHAs) by *Pseudomonas oleovorans*. *J. Biol. Chem.*, 266: 2191-2198.
23. Kaneko, T. *et al.* 1996. Sequence analysis of the genome of the unicellular cyanobacterium *Synechocystis* sp. strain PCC6803. II. Sequence determination of the entire genome and assignment of potential protein-coding regions. *DNA Res.*, 3: 109-136.
24. Kunst, N. *et al.* 1997. The complete genome sequence of the Gram-positive bacterium *Bacillus subtilis*. *Nature*, 390: 249-256.
25. Lauzier, C., R.H. Marchessault, P. Smith, and H. Chanzy. 1992. Structural study of isolated poly( $\beta$ -hydroxybutyrate) granules. *Polymer*, 33: 823-827.
26. Lee, S.Y. 1995. Bacterial polyhydroxyalkanoates. *Biotechnology & Engineering*, 49: 1-14.
27. Liebergesell, M., B. Schmidt, and A. Steinbüchel. 1992. Isolation and identification of granule-associated proteins relevant for poly(hydroxyalkanoic acid) biosynthesis in *Chromatium vinosum* D. *FEMS Microbiol. Lett.*, 99: 227-232.
28. Liebergesell, M. and A. Steinbüchel. 1992. Cloning and nucleotide sequences of genes relevant for biosynthesis of poly(3-hydroxybutyric acid) in *Chromatium vinosum* strain D. *Eur. J. Biochem.*, 209: 135-150.

29. Liebergesell, M. and A. Steinbüchel. 1993. Cloning and molecular analysis of the poly (3-hydroxybutyric acid) biosynthetic genes of *Thiocystis violacea*. *Appl. Microbiol. Biotechnol.*, 38: 493-501.
30. Lundgren, D.G., R.M. Pfister, and J.M. Merrick. 1964. Structure of poly- $\beta$ -hydroxybutyric acid granules. *J. Gen. Microbiol.*, 34: 441-446.
31. Magni, C., P. Marini, and D. de Mendoza. 1995. Extraction of RNA from gram-positive bacteria. *Biotechniques*, 19: 882-884.
32. McCool, G.J., T. Fernandez, N. Li, and M.C. Cannon. 1996. Polyhydroxyalkanoate inclusion-body growth and proliferation in *Bacillus megaterium*. *FEMS Microbiol. Lett.*, 137: 41-48.
33. Miller, J.H. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY:
34. Moran, C.P. Jr., N. Lang, S.F.J. LeGrice, G. Lee, M. Stephens, A.L. Sonnenshein, J. Pero, and R. Losick. 1982. Nucleotide sequences that signal the initiation of transcription and translation in *Bacillus subtilis*. *Mol. Gen. Genet.*, 186: 339-346.
35. Morbidoni, H.R., D. de Mendoza, and J.E. Cronan. 1996. *Bacillus subtilis* acyl carrier protein is encoded in a cluster of lipid biosynthesis genes. *J. Bacteriol.*, 178: 4794-4800.
36. Pieper-Furst, U., M.H. Madkour, F. Mayer, and A. Steinbüchel. 1994. Purification and characterization of a 14-kilodalton protein that is bound to the surface of polyhydroxyalkanoic acid granules in *Rhodococcus ruber*. *J. Bacteriol.*, 176: 4328-4337.

37. Pieper-Furst, U., M.H. Madkour, F. Mayer, and A. Steinbüchel. 1995.  
Identification of the region of a 14-kilodalton protein of *Rhodococcus ruber* that  
is responsible for the binding of this Phasin to polyhydroxyalkanoic acid granules.  
*J. Bacteriol.*, 177: 2513-2523.
38. Sambrook, J., E.F. Fritsch & T. Maniatis. 1989. Molecular Cloning: A Laboratory  
Manual., 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,  
NY.
39. Shark, K.B., F.D. Smith, P.R. Harpending, and J.L. Rasmussen. 1991. Biolistic  
transformation of a procaryote, *Bacillus megaterium*. *Appl. Environ. Microbiol.*,  
57: 480-485.
40. Simon, R., Priefer, U. & Pühler, A. 1983. In A. Pühler (Ed.), Molecular genetics  
of the bacteria-plant interaction. Springer, Berlin. p. 98-106.
41. Steinbüchel, A. 1991. Polyhydroxyalkanoic acids. p. 123-213. In D. Byrom  
(Ed.), Biomaterials, novel materials from biological sources. Macmillan  
Publishers Ltd., Basingstoke, England.
42. Steinbüchel, A., K. Aerts, W. Babel, C. Follner, M. Liebergesell, M.H. Madkour,  
F. Mayer, U. Pieper-Furst, A. Pries, H.E. Valentin, and R. Wieczorek. 1995.  
Considerations on the structure and biochemistry of bacterial  
polyhydroxyalkanoic acid inclusions. *Can. J. Microbiol.*, 41: 94-105.
43. Steinbüchel, A., E. Hustede, M. Liebergesell, U. Pieper, A. Timm, and H.  
Valentin. 1992. Molecular basis for biosynthesis and accumulation of  
polyhydroxyalkanoic acids in bacteria. *FEMS Microbiol. Rev.*, 103: 217-230.

44. Steinbüchel, A. and H.G. Schlegel. 1991. Physiology and molecular genetics of poly( $\beta$ -hydroxyalkanoic acid) synthesis in *Alcaligenes eutrophus*. *Mol. Microbiol.*, 5: 535-542.
45. Steinbüchel, A. and H.E. Valentin. 1995. Diversity of bacterial polyhydroxyalkanoic acids. *FEMS Microbiol. Lett.*, 128: 219-228.
46. Vary, P. 1993. The genetic map of *Bacillus megaterium*, p. 475-481. In A.L. Sonenshein, J.A. Hoch & R. Losich (Eds.), *Bacillus subtilis* and other gram positive bacteria. American Society for Microbiology, Washington, D.C.
47. Wang, W.S. and D.G. Lundgren. 1969. Poly- $\beta$ -hydroxybutyrate in the chemolithotrophic bacterium *Ferrobacillus ferrooxidans*. *J. Bacteriol.*, 97: 947-950.
48. Wieczorek, R., A. Pries, A. Steinbüchel, and F. Mayer. 1995. Analysis of a 24-kilodalton protein associated with the polyhydroxyalkanoic acid granules in *Alcaligenes eutrophus*. *J. Bacteriol.*, 177: 2425-2435.
49. Wieczorek, R., A. Steinbüchel, and B. Schmidt. 1996. Occurrence of polyhydroxyalkanoic acid granule-associated proteins related to the *Alcaligenes eutrophus* H16 GA24 protein in other bacteria. *FEMS Microbiol. Lett.*, 135: 23-30.
50. Hein, S., Tran, H., and A. Steinbüchel. 1998. *Synechocystis* sp. PCC6803 possesses a two-component polyhydroxyalkanoic acid synthase similar to that of anoxygenic purple sulfur bacteria. *Arch. Microbiol.*, 170(3): 162-70.

51. Steinbüchel, A., Hustede, E., Liebergesell, M., Pieper, U., Timm, A., and H. Valentin. 1992. Molecular basis for biosynthesis and accumulation of polyhydroxyalkanoic acids in bacteria. *FEMS Microbiol. Rev.* 103: 217-230.
52. Basak, A., Boudreault, A., Chen, A., Chretien, M., Seidah, N.G., and C. Lazure. 1995. Application of the multiple antigenic peptides (MAP) strategy to the production of prohormone convertases antibodies: synthesis, characterization and use of 8-branched immunogenic peptides. *J. Pept. Sci.* 1(6): 385-95.
53. Slater, S., K.L. Houmiel, M. Tran, T.A. Mitsky, T.B. Taylor, S.R. Padgett, and K.J. Gruys. 1998. Multiple  $\beta$ -ketothiolases mediate poly( $\beta$ -hydroxyalkanoate) copolymer synthesis in *Ralstonia eutropha*. *J. Bacteriol.* 180: 1979-1987.
54. Fukui, T., N. Shiomi, and Y. Doi. 1998. Expression and characterization of (R)-specific enoyl coenzyme A hydratase involved in polyhydroxyalkanoate biosynthesis in *Aeromonas caviae*. *J. Bacteriol.* 180: 667-6673.
55. Boynton, Z.L., G.N. Bennett, and F.B. Rudolph. 1996. Cloning, sequencing, and expression of clustered genes encoding b-hydroxybutyryl-coenzyme A (CoA) dehydrogenase, crotonase, and butyryl-CoA dehydrogenase from *Clostridium acetobutylicum* ATCC 824. *J. Bacteriol.* 178: 3015-3024.
56. Liebergesell, M., F. Mayer, and A. Steinbüchel. 1993. Analysis of polyhydroxyalkanoic acid-biosynthesis genes of anoxygenic phototrophic bacteria reveals synthesis of a polyester exhibiting an unusual composition. *Appl. Microbiol. Biotechnol.* 40:292-300.

## **WHAT IS CLAIMED IS:**

1. A nucleic acid segment comprising a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein, wherein the nucleic acid sequence is selected from the group consisting of:
  - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;
  - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof;
  - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and
  - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9.
2. An isolated 3-keto-acyl-CoA reductase protein comprising an amino acid sequence selected from the group consisting of:
  - an amino acid sequence at least about 80% identical to SEQ ID NO:9; and
  - an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9.
3. A recombinant vector comprising in the 5' to 3' direction:
  - a) a promoter that directs transcription of a structural nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein;
  - b) a structural nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein; wherein the structural nucleic acid sequence is selected from the group consisting of:
    - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;
    - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof;
    - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and
    - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and
  - c) a 3' transcription terminator.
4. A recombinant host cell comprising a nucleic acid segment encoding a 3-keto-acyl-CoA reductase protein, wherein the nucleic acid segment is selected from the group consisting of:
  - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;
  - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof;



7. A method of preparing host cells useful to produce a 3-keto-acyl-CoA reductase protein, the method comprising:
  - a) selecting a host cell;
  - b) transforming the selected host cell with a recombinant vector having a structural nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein, wherein the structural nucleic acid sequence is selected from the group consisting of:
    - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;
    - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof;
    - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and
    - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and
  - c) obtaining transformed host cells.
  
8. A method of preparing plants useful to produce a 3-keto-acyl-CoA reductase protein, the method comprising:
  - a) selecting a host plant cell;
  - b) transforming the selected host plant cell with a recombinant vector having a structural nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein, wherein the structural nucleic acid sequence is selected from the group consisting of:
    - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;
    - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof;
    - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and
    - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9;
  - c) obtaining transformed host plant cells; and
  - d) regenerating the transformed host plant cells.
  
9. A nucleic acid segment comprising a nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein, wherein the nucleic acid sequence is selected from the group consisting of:
  - a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;
  - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;
  - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and

a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11.

10. An isolated polyhydroxyalkanoate synthase protein comprising an amino acid sequence selected from the group consisting of:  
an amino acid sequence at least about 80% identical to SEQ ID NO:11; and  
an amino acid sequence that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11.
11. A recombinant vector comprising in the 5' to 3' direction:
  - a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein;
  - b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein; wherein the structural nucleic acid sequence is selected from the group consisting of:  
a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;  
a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;  
a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and  
a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and
  - c) a 3' transcription terminator.
12. A recombinant host cell comprising a nucleic acid segment encoding a polyhydroxyalkanoate synthase protein, wherein the nucleic acid segment is selected from the group consisting of:  
a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;  
a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;  
a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and  
a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11.
13. A genetically transformed plant cell comprising in the 5' to 3' direction:
  - a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein;

- b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein; wherein the structural nucleic acid sequence is selected from the group consisting of:
    - a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;
    - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;
    - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and
    - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11;
  - c) a 3' transcription terminator; and
  - d) a 3' polyadenylation signal sequence that directs the addition of polyadenylate nucleotides to the 3' end of RNA transcribed from the structural nucleic acid sequence.
  
- 14. A genetically transformed plant comprising in the 5' to 3' direction:
  - a) a promoter that directs transcription of a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein;
  - b) a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein; wherein the structural nucleic acid sequence is selected from the group consisting of:
    - a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;
    - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;
    - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and
    - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11;
  - c) a 3' transcription terminator; and
  - d) a 3' polyadenylation signal sequence that directs the addition of polyadenylate nucleotides to the 3' end of RNA transcribed from the structural nucleic acid sequence.
  
- 15. A method of preparing host cells useful to produce a polyhydroxyalkanoate synthase protein, the method comprising:
  - a) selecting a host cell;
  - b) transforming the selected host cell with a recombinant vector having a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein, wherein the structural nucleic acid sequence is selected from the group consisting of:
    - a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;

- a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;
- a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and
- a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and
- c) obtaining transformed host cells.

16. A method of preparing plants useful to produce a polyhydroxyalkanoate synthase protein, the method comprising:
  - a) selecting a host plant cell;
  - b) transforming the selected host plant cell with a recombinant vector having a structural nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein, wherein the structural nucleic acid sequence is selected from the group consisting of:
    - a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;
    - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;
    - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and
    - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11;
  - c) obtaining transformed host plant cells; and
  - d) regenerating the transformed host plant cells.
17. A method for the preparation of polyhydroxyalkanoate, the method comprising:
  - a) obtaining a cell comprising:
    - a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein;
    - and
    - a nucleic acid sequence encoding a PHA synthase protein;
 wherein:
    - the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is not naturally found in the cell;
    - the nucleic acid sequence encoding a PHA synthase protein is not naturally found in the cell;
    - the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is selected from the group consisting of:
      - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;
      - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof;

- a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and
      - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and
    - the nucleic acid sequence encoding a PHA synthase protein is selected from the group consisting of:
      - a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;
      - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;
      - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and
      - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and
  - b) culturing the cell under conditions suitable for the preparation of polyhydroxyalkanoate.
18. A method for the preparation of polyhydroxyalkanoate, the method comprising:
- a) obtaining a plant comprising:
    - a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein;
    - and
    - a nucleic acid sequence encoding a PHA synthase protein;
 wherein:
    - the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is not naturally found in the plant;
    - the nucleic acid sequence encoding a PHA synthase protein is not naturally found in the plant;
    - the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is selected from the group consisting of:
      - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;
      - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof;
      - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and
      - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using

- SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and
      - the nucleic acid sequence encoding a PHA synthase protein is selected from the group consisting of:
        - a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;
        - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;
        - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and
        - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and
    - b) growing the plant under conditions suitable for the preparation of polyhydroxyalkanoate.
  19. A method for the preparation of polyhydroxyalkanoate, the method comprising:
    - a) obtaining a cell comprising:
      - a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein;
      - and
      - a nucleic acid sequence encoding a PHA synthase protein;wherein:
      - the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is not naturally found in the cell;
      - the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is selected from the group consisting of:
        - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;
        - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof;
        - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and
        - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and
    - b) culturing the cell under conditions suitable for the preparation of polyhydroxyalkanoate.
  20. A method for the preparation of polyhydroxyalkanoate, the method comprising:
    - a) obtaining a plant comprising:

- a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein;
- and
- a nucleic acid sequence encoding a PHA synthase protein;
- wherein:
  - the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is not naturally found in the plant;
  - the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is selected from the group consisting of:
    - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;
    - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:8 or the complement thereof;
    - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:9; and
    - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:9 as an antigen, the antibody being immunoreactive with SEQ ID NO:9; and
- b) growing the plant under conditions suitable for the preparation of polyhydroxyalkanoate.


21. A method for the preparation of polyhydroxyalkanoate, the method comprising:
- a) obtaining a cell comprising:
    - a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein;
    - and
    - a nucleic acid sequence encoding a PHA synthase protein;
    - wherein:
      - the nucleic acid sequence encoding a PHA synthase protein is not naturally found in the cell;
      - the nucleic acid sequence encoding a PHA synthase protein is selected from the group consisting of:
        - a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;
        - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;
        - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and
        - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and

- b) culturing the cell under conditions suitable for the preparation of polyhydroxyalkanoate.
- 22. A method for the preparation of polyhydroxyalkanoate, the method comprising:
  - a) obtaining a plant comprising:
    - a nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein;
    - and
    - a nucleic acid sequence encoding a PHA synthase protein;
 wherein:
    - the nucleic acid sequence encoding a PHA synthase protein is not naturally found in the plant;
    - the nucleic acid sequence encoding a PHA synthase protein is selected from the group consisting of:
      - a nucleic acid sequence at least about 80% identical to SEQ ID NO:10;
      - a nucleic acid sequence that hybridizes under stringent conditions to SEQ ID NO:10 or the complement thereof;
      - a nucleic acid sequence encoding a protein at least about 80% identical to SEQ ID NO:11; and
      - a nucleic acid sequence encoding a protein that is immunoreactive with an antibody prepared using SEQ ID NO:11 as an antigen, the antibody being immunoreactive with SEQ ID NO:11; and
  - b) growing the plant under conditions suitable for the preparation of polyhydroxyalkanoate.
- 23. A method for the preparation of polyhydroxyalkanoate, the method comprising:
  - a) obtaining a recombinant host cell comprising:
    - a nucleic acid sequence encoding a  $\beta$ -ketothiolase protein;
    - a nucleic acid sequence encoding a 3-ketoacyl-CoA reductase protein;
    - a nucleic acid sequence encoding a polyhydroxyalkanoate synthase protein;
    - a nucleic acid sequence encoding a  $\beta$ -hydroxyacyl-CoA dehydrase; and
    - a nucleic acid sequence encoding an acyl-CoA dehydrogenase protein or an enoyl-CoA reductase protein; and
  - b) culturing the recombinant host cell under conditions suitable for the preparation of polyhydroxyalkanoate; wherein:
    - the polyhydroxyalkanoate comprises C6, C8, or C10 monomer subunits;
    - the nucleic acid sequence encoding a 3-keto-acyl-CoA reductase protein is selected from the group consisting of:
      - a nucleic acid sequence at least about 80% identical to SEQ ID NO:8;



## ABSTRACT

A 7,916 base pair nucleic acid fragment from *Bacillus megaterium* is disclosed. The fragment encodes five proteins, PhaP, PhaQ, PhaR, PhaB, and PhaC, shown or inferred to be involved in the biosynthesis of polyhydroxyalkanoate materials.



**FIGURE 1**





FIGURE 2A





**FIGURE 2C**

B.meg. MAIPYVQFWEK-----LIK S-----MPS E----YKSS A-----RRFKRAN--- 31  
P.ole. MSNKNNIELQRQASENTLGLNPVIGIRRKD ULS SARTVLRQAVRQPLHSAKHVAHFGLLEKNVLLGKSSLAHESDDRRFNDPAWSNNPLYRRRYLQTYLAW 100

B.meg. -----EI MTEAEPEVCLT-----P KE-----VIWKKNK 55  
P.ole. RKELQDWIGNSDLSPQDISRGQFVINL MEAMPTNTLSNPAAVKRFFETGGKSLLDGLSNLA KDLVNNGGMPSQVNMDAFEVGKNLGTSEGAVYRNDV 200


B.meg. AKUYRMTPVKDNILKTPHLLVYALINKPYILDLTPGNSLVEYLLNRGFDVYLLDVGTPGLEDSNMKDEYIVDYIPKMAKKVLRTSKSPDISVLGYCNGG 155  
P.ole. LELIQYKPHTEQVILARPLVWPPQINKFYVFDLSPEKSLARNCIRSQQTFIISWRNPTKAQREWGLSTYILDALKEAVDAVIAITGSKDINMLGAGSGG 299

B.meg. ----TMTSIF AALNEDLPIKNLIFMTSPFDFSDTGLYGAFLLDDRYFNLDNAVDTFGNIPPIMIDFGNKM--LKPIITNFGYPYVTLVDRSENQRFVESWKIL 249  
P.ole. ITCTALVGHYAALGHN-KVNAITLLVSVLITTMNQVAHFVLEQILEAAKR-HSYQAGVLEGSEMAKVFAWMPINDLIWNYVNNYLLGNEPPVFDI-- 395

B.meg. MQFWVADGIPFAGEAYRQWIRDFYQCKLINGE-LEVRGRKVDLKNIRANILNIASRDHIAAPHQVAALMDAVSSEDEYKILQTGHVSVVFGPKA-VK 347  
P.ole. F--WNNLTTRLPA-AFHGDLIEMFKS NPLTRPDALVCCCTPIDLKQVSCDLYSLAGTNDIHT-IPVQSCYRSAHLFGGKIIEFVLSNSGLIQSILNPPGNPK 491

B.meg. ETYPSIG D-----WIEKRS-----K 362  
P.ole. ARFMTGALRPGDPVAWQENATKHADSWWLHWIIGERAGELEKAPTRLGNRAYAAGEASPGTYVHER 559

FIGURE 3



**FIGURE 4**






FIGURE 5A




**FIGURE 5B**


pGM16.2




**FIGURE 5C**



**FIGURE 5D**



**FIGURE 5E**



**FIGURE 5F**

00473040-01000




FIGURE 6

002073" 04052460




FIGURE 7

002070" 04052460





FIGURE 8

PhaC_Bm	MAIPYVQEWELIKSMPSEYKSSARRFKRAYEIMTTEAEPEVGLTPKEVIWKKNKAKLYR
PhaC_Tv	-----MRPIDIRPDKLAQEMLDYTSKLGQGEMENLLNADAIDTGVSPKEAVYSEDKLVLYR
	. . . . * . . . * . . . * . . . . * . . . . * . . . . *
PhaC_Bm	Y-TPVKDNLHKTPILLVYALINKPYILDTPGNSLVEYLLNRGFDVYLLDWGTPGLEDSN
PhaC_Tv	YDTPAGVTPQKTPLLIVYALVNRPYMTDIQEDRSTIKGLLATGQDVYLIDWGYPDQADSA
	* * * . . . . . * . . . . * . . . . * . . . . * . . . . *
PhaC_Bm	MKLDDYIVDYIPKAAKKVLRTSKSPDLSVLGYCMGGTMTSIFAALNEDLPIKNLIFMTSP
PhaC_Tv	LTLDDYINGYIDSCVDYLCETHEVDQVNILGICQGGAFSLMYASLHPDK-VKNLVTMVTP
	. * . . . . * . . . . * . . . . * . . . . * . . . . *
PhaC_Bm	FDFSDTG-LYGAFLLDDRYFNLDKAVDTFGNIPPEMIDFGNKMLKPITNFYGPYVTLVDRS
PhaC_Tv	VDFKTPGNLLSAWVQN--VDIDLAVDTMGNIPEGELNWTFLSLKPFSLTGQKYVNMVDML
	* * * * * . . . . . * . . . . * . . . . * . . . . *
PhaC_Bm	ENQRFVESWKLMQKWVADGIPFAGEAYRQWIRDFYQQNKLINGELEVRGRKVDLKNIKAN
PhaC_Tv	DDPDKVKNFLRMEKWIFDSDPDQAGETFRQFTKDFYQKNGFINGGVKLGKKEIDLKNVDCP
	. * . . . . * . . . . * . . . . * . . . . * . . . . *
PhaC_Bm	ILNIAASRDHIAMPHQVAALMDAVSSEDKEYKLLQTGHVSVVFGPKAVKETYP SIGDWLE
PhaC_Tv	VLNIYALQDHLVPPDASKALNPWSAARTYTELAFPGGHIGIYVSGKAQKEVTPAIGKWLN
	. * . . . . * . . . . * . . . . * . . . . * . . . . *
PhaC_Bm	KRSK
PhaC_Tv	ERS-
	**

FIGURE 9

## Proposed Pathway for Production of PHA C4/C6 Copolymer from Acetyl-CoA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Maura C. Cannon et al.

Serial No.: To be Assigned

Filed: January 7, 2000

For: POLYHYDROXYALKANOATE  
BIOSYNTHESIS ASSOCIATED  
PROTEINS AND CODING REGION IN  
*BACILLUS MEGATERIUM*

Group Art Unit: To be Assigned

Examiner: To be Assigned

Atty. Dkt. No.: MOBT:212/KAM

STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(f)

**BOX SEQUENCE**

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Submitted herewith is a computer readable form and a paper copy of the sequence listing of those sequences in the captioned patent application. The computer readable form of the sequence listing is the same as the paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed computer readable and paper forms of the sequence listing.

CERTIFICATE OF EXPRESS MAILING

NUMBER EL392859935US

DATE OF DEPOSIT January 7, 20000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

  
Signature

Respectfully submitted,



Christopher J. Buntel, Ph.D.

Reg. No. 44,573

Agent for Applicants

ARNOLD, WHITE & DURKEE  
P.O. Box 4433  
Houston, Texas 77210-4433  
(713) 787-1400

Date: January 7, 2000

002070"04062460

# SEQUENCE LISTING

<110> McCool, Gabriel J.  
Cannon, Maura C.  
Cannon, Francis C.  
Valentin, Henry E.  
Gruys, Kenneth J.

<120> POLYHYDROXYALKANOATE BIOSYNTHESIS ASSOCIATED PROTEINS  
AND CODING REGION IN BACILLUS MEGATERIUM

<130> MOBT212

<140> 60/115,092

<141> 1999-01-07

<160> 29

<170> PatentIn Ver. 2.1

<210> 1

<211> 7916

<212> DNA

<213> Bacillus megaterium

<400> 1

```
aagcttaaca aaagggttaga gggcttttaa ttgacttatt aatgaacctt ttataaaata 60
aaaacaactt aatacattta cttcttacgg agtaaagggg agtagcgtca gggaaacctg 120
aaacaaagtc gtcattacat ggagtattcc atcggctttg ttggcataat gattatgctt 180
agcaagacct ttgccatatt tggcaaaggt ctttttgtgt tttattccgg taatgaggat 240
aaataaactt atacaaagaa acgagagggg atttttatgg atgcatcact tttgttagag 300
tatggatggg tattgctagt gctggttgca ttagaaggaa ttttggcggc ggataatgct 360
cttgtgatgg ctattatggt caaacattta ccggaagaaa aacgcaagaa ggcattattt 420
tacggattag ccggtgcctt tttttttaga tttggttcgt tgttcttgat ttcatTTTTA 480
gtcgcgctat ggcagcttca agctatagga gccatttact tattgttcat ttccattaat 540
catattgtga agcgatatgt gaaaaaagac gatcatgaaa aagtgaagaa agcagacgag 600
aaaaagggct caggttttctg gatgacgggt ttaaaagtag aaatagcaga cattgctttt 660
gccgttgatt caatttttggc cgtctgtggc ctccgcttca cgttgccaac aacaaatctt 720
cctcaaattg gcggactcga cggcggacaa ttcttggtga tcttcgccgg aggaattatg 780
ggattaatta ttatgcgttt tgctgcaact tggttcgtca agctattaaa tacgcgcccc 840
ggcctagaaa cggcggcttt tgctattgta ggctgggtag gagttaagtt agcgggtctat 900
acccttgctc atccagagtt aggtattatt aatgaacatt tccttgaatc aaaagtgtgg 960
aaaattacgt tttggattgt gttacttggc atagctgctt caggctggtt tctatctaaa 1020
aataaagaac aaactgatct tgaaggctca gagaaagaaa aagaatcgtt aaaaaaaatt 1080
gaaaatcaat aataaaaaaa acgcgccttc aatgttaatt gaaggcgcgt tttttatagg 1140
gggataaaat acctagttaa gattgtttta ataaagggta aaagaattaa ttactgttta 1200
attactgtat atccgaatgt tttgcttttt cgttcatatt ctgtagagaa cagagccgtg 1260
agtaattcag ttcaatgaag tttatttcag tttataaaca tatatttcaa atgtatgtta 1320
attggtaaaa ttgagctatt atgggttata ataaaggaaa attaaaagga gcagagcgct 1380
tctcaaccct gttcgtcatc aaaagaatgg atattaacat ggtataaagc aactgagtat 1440
agtaaaagag gtgaagccaa tgctcacaaa agttcaaacg cctccatcgc ttgaaacgct 1500
tgtactgacg attcagcaag gggataaaca attacataat gaaatgattc aacaatataa 1560
accgtttatt gctaaagttg tttcagctgt atgtaaacgt tatataagtg aagctgacga 1620
```

tgaatttagc attggtctga ttgcatttaa tgaagccatt gaaaattaca caatccaaaa 1680  
 aggacgatct cttcttgcat ttgcggaact tattattaaa agaagagtaa tgcactatat 1740  
 tcgaaaagaa aagcgaaatc aaacgctgct ctataaccga attgaaaatg aagggttttat 1800  
 tcaaggtaag gtagaaaggg atatatcgct ttctaactat aaaaggcaaa gtgaaacttc 1860  
 atatattcaa gaggaaatga cttatTTTTg tcaggcgcta aaattgttta aattaactct 1920  
 tgaagacatt attaacacgt ctcctaaaca taaggatgca aggggaaatg cagtggaggt 1980  
 tgcattctttt atcgtcaatg aaaaagaatt aaaagataag ctgtttttta agcggcagct 2040  
 tcctattcgc ttgattgaaa aacatgtcaa agtaagccgg aaaacaattg aaagaaaccg 2100  
 taaatatatt atcgcgatgg ttattatatt agcgggggac tacgtgtatt taaaagacta 2160  
 tattatgtaa gaaaaaggca cacgcagggt ctttttttta gccatgttat gaaattatgt 2220  
 tttatTTTTg tgtgctgccg ctttaagtga cttgagcttg ttgcaccaag cgttttgtga 2280  
 tttctccgcc tactgaaccg ttgctgcgtg cagcagtgct agaacctaga gttaccccaa 2340  
 attcttgagc gatttcatat ttatattgat ctaaaaattg ttctactcct ggtgttaata 2400  
 gtttatttgt tctagccatg attagtcata tcctttttta gtggtacagc agttcactgc 2460  
 tgtacctgta ttatttgttg tttcctatTT tgcatactgg taatggtttg caagaaagta 2520  
 taaaaaagcc cagctttcaa agaagctggg cttttttata tattatttta caactgcata 2580  
 ttgctcaaga gactgagcaa atgacttttg aagagatttt acttgttcta cgtatgcata 2640  
 agatacgtgt tgggaattctt ggcgcgtttt cttttgctct tctactaatt gtgttactac 2700  
 ttgatgatat tgttcttgcg cttgctttac taaagaatag cttgatttgc tttggttaaa 2760  
 aaaaagctct tgtaatttat ttaatgtctt atgctgcggg tttgtccatt cttcataaga 2820  
 atcggcaaca gcgtttccag ctgtttttac taagttttca actgtttttt gttgaaggct 2880  
 ttccaattca gctttccatt gtttgtctgt tgcttgaagt tgttcaactg cttttgttac 2940  
 aaattcttgc tgttgcctca gtgcttttaa cgtccattgc tcaatttgtt tgtttccgtc 3000  
 tgcaatgttt tgtaaccctt ttgtccattg tcccacatt gcatcaatta ctgtatcata 3060  
 ctttactggt gacataatca aattcctcct tgaataattt ggtctggcga acagttatcg 3120  
 taatgaacaa aacgttaaag aagaaattcg tagttgtgtg ataaacctaa cattccgcgc 3180  
 tcgctggttg accgtgaaat ttaacattat attaggaac gcagatgtac tgcgtgaatc 3240  
 cttttaatcg ttttcttctt cttttgatTC ttttgacttt ttagaagaag aagagctaaa 3300  
 agggaacaac atgtcgggat acatgtgaaa aaatgaatct aacatgtttt gatactgttc 3360  
 aagtgaatta gccacatac ttaaattatt ttccgcggca tctgttaatg aataaatccg 3420  
 gcgtgcaggt ctttcagctg acgtatccca ttgcgatgta atcaagttgt ctttttcaag 3480  
 ctgtctcagc gtgcggtaga catttccctg atcaactgat gtgaatccaa agctcattag 3540  
 ttgctgaatg agcttgtaac catgtagatt ccaccctctt aaacttaaaa gaagaaaagg 3600  
 aaccatcaag ttttttggtg caccgctaatt cgatttttct aagttgtttg aattagaggt 3660  
 gttatctttt tcaactgatc ccaaggtaat cacccttctg aaaaaagaga atttgttttc 3720  
 catatgtgta atttacacct agatgaaaaa attgtcaaca ctttaaaaca ggtctttcaa 3780  
 atacaggaaa aaagaacgat tttttggatt tcgacaaaaa gcgtcaaaaa aattcaaaaa 3840  
 taaacaaaga tttagaattg tttatTTTTg aaaacgtatt tataatagta catgtaggta 3900  
 atttttataa catttataat ttgttggtaa gtgaattgtg aaaagattta cattatccaa 3960  
 taaataaacg caaaattggt tgcgtttact tagagcttct aatatgtcgc ttgtcacatt 4020  
 aagtgtccat attgaaaagg atcactttta acgtacacaa gaaaggagat ggagtttttg 4080  
 aacagcaaaa agtatttgat ccgtttcaag catggaaaga cgtatatgac aaaaccgaat 4140  
 cttactgggg taaagttatt ggggacaata tgaatcgtga agaattttcc cagctcatgg 4200  
 gaaatgtgct aaatatgaac cttcaatatc aacaagcagt aaatgaagta acggggcgct 4260  
 atctgcacca agtaaatgta ccaacaaaag aagatgtagc aaacgttgcg tcattagtca 4320  
 tcaatgtgga agaaaaagta gaattattag aagagcaatt tgacgatcgt tttgatgaat 4380  
 tagaagcaca gcaagaaagt gcatctgctt tgaaaaaaga tgtcactaag ctgaaatctg 4440  
 atgtcaaatc gttagacaaa aaactcgata aagttttatc tcttcttgaa gggcagcaaa 4500  
 aaacacaaga cgagttaaaa gaaacgattc aaaaacaaat taaaactcaa ggtgagcagc 4560  
 ttcaggctca gctgttagaa aaacaagaaa aattagctga aaagccaaag gcagaagcta 4620  
 aatctgaagc aaaaccatca aacgctcaaa aaactgagca gccggctcgc aagtaaggta 4680  
 tcggagattt tataacaaca ttaactgctg tatttacagt aaaaatcctc gctgaagaag 4740  
 caagggggaa atttttcatg acaacattac aaggtaaagt agcaatcgtg acaggcggat 4800

ctaaaggtat	cggggcagca	attacacgtg	agcttgcttc	taatggagta	aaagtagcag	4860
taaactataa	cagcagtaaa	gaatctgcag	aagcaattgt	aaaagaaatt	aaagacaacg	4920
gcggagaagc	tattgcgggt	caagctgcag	tgtcttatgt	agatcaagca	aaacacctaa	4980
tcgaagaaac	aaaagctgcg	tttggccaat	tagacattct	agtaaacaaat	gctggaatta	5040
cgcgcgaccg	ttcattcaag	aagttagggtg	aagaagattg	gaaaaaagta	attgatgtaa	5100
acttacatag	cgtatacaac	acaacatcag	ctgcgctaac	gcacctttta	gaatctgaag	5160
gtggtcgtgt	tatcaatatt	tcatacaatta	ttggccaagc	gggcggattt	ggtcaaaca	5220
actactcagc	tgctaaagca	ggtatgctag	gattcactaa	atcattagct	cttgaactag	5280
ctaagacagg	cgtaacgggt	aatgcaattt	gcccaggatt	tattgaaacg	gaaatgggtga	5340
tggcaattcc	tgaagatggt	cgtgcaaaaa	ttgttgcgaa	aattccaact	cgtcgcttag	5400
gtcacgctga	agaaattgca	cgtggagttg	tttacttagc	aaaagacggc	gcgtacatta	5460
caggacaaca	gttaaacatt	aacggcggct	tatacatgta	ataaatgctg	gccctgactt	5520
ttgtcggggc	tgtgcttggt	aactaactac	taatggaatg	aaaggggtgtg	tatattcgtg	5580
gcaattcctt	acgtgcaaga	gtgggaaaaa	ttaatcaaat	caatgccaa	tgaatataaa	5640
agttctgcaa	gacgttttaa	gcgtgcata	gaaattatga	caacagaagc	ggaaccggaa	5700
gttggattaa	cacaaaaaga	ggttattttg	aaaaagaaca	aagcgaaatt	atatcgctat	5760
acgccagtaa	aagataacct	gcataaaaaca	ccaatcttac	tcgtatatgc	attgatcaat	5820
aaaccgtata	ttttggattt	aacacctgga	aacagccttg	ttgaatactt	attaaaccgc	5880
ggttttgacg	tgtatttgct	tgactgggga	actcctgggc	ttgaagacag	caatatgaag	5940
ctagatgatt	atattgtaga	ttataattcca	aaagcggcga	aaaaggtgct	gcgcacttct	6000
aaatctcctg	atttgtctgt	tcttggttac	tgcatgggcg	gaactatgac	atctattttt	6060
gctgcattaa	atgaagactt	gccgattaaa	aacttaattt	ttatgacaag	tcattttgat	6120
ttttcggata	caggtttata	cggagcattc	ctagatgata	gctactttaa	tttagataaa	6180
gcagtagata	cattcggaaa	catccctcca	gagatgattg	actttggaaa	caagatgtta	6240
aagccaatca	cgaatttcta	cggcccgtat	gtaacgttgg	tggaccggtc	ggaaaatcag	6300
cggtttgttg	aaagctggaa	gctaattgcaa	aagtggttg	ctgacgggaat	cccatttgct	6360
ggcgaagcct	atcgtcagtg	gattcgtgac	ttctatcaac	aaaacaaact	aatcaatggt	6420
gaacttgaag	ttcgcggacg	caaagtagat	ttaaaaaata	ttaaagctaa	tatttttaaac	6480
aatgctgcta	gccgtgatca	tattgcgatg	ccgcatcaag	tggcagcttt	aatggacgct	6540
gtttcaagtg	aagataaaga	gtataaattg	ttgcaaacag	gtcacgtatc	tgttgtattt	6600
ggtccaaaag	cagtgaagga	aacataatcct	tcaatcggcg	attggctaga	aaaacgctct	6660
aaataaaaata	aagacgaggc	tgagacaaaa	gtatttttagc	cgaagtgaaa	aacgaaccac	6720
tgatatcagt	ggttcgtttt	tttgataaaa	cagacaatat	cgagtgatga	ttcttttatct	6780
ggactgatgg	gatttatgat	atctaattgac	aagtgagatg	acttctttta	tactaatgta	6840
gtcaccttct	taaacatggg	attttttaca	tggatatagc	tattcatgta	acaatgagta	6900
tgctttgaga	agaaagaaga	aaactatttag	tattataatg	aaaaaggaat	gtcagattat	6960
gccacaacca	tggaaacgac	gagtaaggca	gatgtcttca	gctcaaatta	ttgttacatt	7020
ttacatagtg	gctgttacgc	ttgggtttct	attacttagt	attccagaag	ctttaaggcc	7080
aggagcaaag	ttagcattta	ttgatcgctt	atttattgcc	gttagtgcg	taagtgtaac	7140
agggctgaca	cctgtctcga	ctccagatac	atttagtaca	acgggctatt	ttttactcgt	7200
ttttattttt	caaatcggtg	gtattgggtg	aatgacactc	agtacattta	tttggatgat	7260
tttaggtaaa	aaaatcggtc	tgaaggaaag	tcagctcatt	atgacgggacc	ataatcaatc	7320
ccgtttatca	ggattagttg	atttgatgag	aaatatttta	tttattattt	ttgccattga	7380
actagttggc	gccattattt	tagggttaca	ttttctccgt	tattattoga	gctggacaga	7440
tgcgtttttg	catggtttct	ttgcttctgt	cagtgctaca	acaaatgctg	gcttcgatata	7500
tacaggatct	tcattttattc	cgtatgccca	tgattatttc	gtacaagtgg	taaccgttat	7560
tttaattacg	cttggagcga	ttggattccc	tgtattaatt	gaaatcaagc	actatttttt	7620
aacatttaaa	gataagcgta	aatttcaatt	ttcgctattt	acgaagctaa	cgactattat	7680
gtttttttctg	ctgttaggag	ggggaacaat	cttgattctt	gtgctagagc	attcaggatt	7740
tctagcagat	aagtcttggg	atgaatcggt	tttttatgcg	tttttccaat	ccgctgccac	7800
aaggagcggg	ggagtggcga	ccatgaatat	taatgagttt	tcacttccta	cgtaaattat	7860
gatgagcgcg	atgatgttta	tcggtgcttc	accgagttca	gtaggggggag	gaattc	7916

<210> 2  
<211> 510  
<212> DNA  
<213> Bacillus megaterium

<400> 2  
atgtcaacag taaagtatga tacagtaatt gatgcaatgt gggaacaatg gacaaagggg 60  
ttacaaaaca ttgcagacgg aaacaaacaa attgagcaat ggacgttaaa agcacttgag 120  
caacagcaag aatttgtaac aaaagcagtt gaacaacttc aagcaacaga caaacaatgg 180  
aaagctgaat tggaagacct tcaacaaaaa acagttgaaa acttacgtaa aacagctgga 240  
aacgctgttg ccgattctta tgaagaatgg acaaaccgca cgcataaagc attaaataaa 300  
ttacaagagc ttttttttaa ccaaagcaaa tcaagctatt ctttagtaaa gcaagcgcaa 360  
gaacaatatc atcaagtagt aacacaatta gtagaagagc aaaagaaaac gcgccaagaa 420  
ttccaacacg tatctgatgc atacgtagaa caagtaaaat ctcttcaaaa gtcatttgct 480  
cagtctcttg agcaatatgc agttgtaaaa 510

<210> 3  
<211> 170  
<212> PRT  
<213> Bacillus megaterium

<400> 3  
Met Ser Thr Val Lys Tyr Asp Thr Val Ile Asp Ala Met Trp Glu Gln  
1 5 10 15  
Trp Thr Lys Gly Leu Gln Asn Ile Ala Asp Gly Asn Lys Gln Ile Glu  
20 25 30  
Gln Trp Thr Leu Lys Ala Leu Glu Gln Gln Gln Glu Phe Val Thr Lys  
35 40 45  
Ala Val Glu Gln Leu Gln Ala Thr Asp Lys Gln Trp Lys Ala Glu Leu  
50 55 60  
Glu Asp Leu Gln Gln Lys Thr Val Glu Asn Leu Arg Lys Thr Ala Gly  
65 70 75 80  
Asn Ala Val Ala Asp Ser Tyr Glu Glu Trp Thr Asn Arg Thr His Glu  
85 90 95  
Ala Leu Asn Lys Leu Gln Glu Leu Phe Phe Asn Gln Ser Lys Ser Ser  
100 105 110  
Tyr Ser Leu Val Lys Gln Ala Gln Glu Gln Tyr His Gln Val Val Thr  
115 120 125  
Gln Leu Val Glu Glu Gln Lys Lys Thr Arg Gln Glu Phe Gln His Val  
130 135 140  
Ser Asp Ala Tyr Val Glu Gln Val Lys Ser Leu Gln Lys Ser Phe Ala  
145 150 155 160

Gln Ser Leu Glu Gln Tyr Ala Val Val Lys  
165 170

<210> 4  
<211> 438  
<212> DNA  
<213> Bacillus megaterium

<400> 4  
ttgggatcaa gtgaaaaaga taacacctct aattcaaaca acttagaaaa atcgattagc 60  
ggtgcaccaa aaaacttgat ggttcctttt cttcttttaa gtttaagagg gtggaatcta 120  
catgggttaca agctcattca gcaactaatg agctttggat tcacatcagt tgatcagggga 180  
aatgtctacc gcacgctgag acagcttgaa aaagacaact tgattacatc gcaatgggat 240  
acgtcagctg aaggacctgc acgccggatt tattcattaa cagatgccgg cgaacaatat 300  
ttaagtatgt gggctaattc acttgaacag tatcaaaaca tgtttagattc attttttcac 360  
atgtataccg acatgttggt cccttttagc tcttcttctt ctaaaaagtc aaaagaatca 420  
aaagaggaag aaaacgat 438

<210> 5  
<211> 146  
<212> PRT  
<213> Bacillus megaterium

<400> 5  
Met Gly Ser Ser Glu Lys Asp Asn Thr Ser Asn Ser Asn Asn Leu Glu  
1 5 10 15  
Lys Ser Ile Ser Gly Ala Pro Lys Asn Leu Met Val Pro Phe Leu Leu  
20 25 30  
Leu Ser Leu Arg Gly Trp Asn Leu His Gly Tyr Lys Leu Ile Gln Gln  
35 40 45  
Leu Met Ser Phe Gly Phe Thr Ser Val Asp Gln Gly Asn Val Tyr Arg  
50 55 60  
Thr Leu Arg Gln Leu Glu Lys Asp Asn Leu Ile Thr Ser Gln Trp Asp  
65 70 75 80  
Thr Ser Ala Glu Gly Pro Ala Arg Arg Ile Tyr Ser Leu Thr Asp Ala  
85 90 95  
Gly Glu Gln Tyr Leu Ser Met Trp Ala Asn Ser Leu Glu Gln Tyr Gln  
100 105 110  
Asn Met Leu Asp Ser Phe Phe His Met Tyr Thr Asp Met Leu Phe Pro  
115 120 125  
Phe Ser Ser Ser Ser Ser Lys Lys Ser Lys Glu Ser Lys Glu Glu Glu  
130 135 140

-100 of 112-

Cannon Application

Asn Asp  
145

<210> 6  
<211> 504  
<212> DNA  
<213> Bacillus megaterium

<400> 6  
atgaatcgtg aagaattttc ccagctcatg ggaaatgtgc taaatatgaa ccttcaatat 60  
caacaagcag taaatgaagt aacggggcgc tatctgcacc aagtaaagt accaacaaaa 120  
gaagatgtag caaacgttgc gtcattagtc atcaatgtgg aagaaaaagt agaattatta 180  
gaagagcaat ttgacgatcg ttttgatgaa ttagaagcac agcaagaaag tgcattctgct 240  
ttgaaaaaag atgtcactaa gctgaaatct gatgtcaaat cgtagacaa aaaactcgat 300  
aaagttttat ctcttcttga agggcagcaa aaaacacaag acgagttaaa agaaacgatt 360  
caaaaacaaa ttaaaactca aggtgagcag cttcaggctc agctgttaga aaaacaagaa 420  
aaattagctg aaaagccaaa ggcagaagct aaatctgaag caaaaccatc aaacgctcaa 480  
aaaactgagc agccggctcg caag 504

<210> 7  
<211> 168  
<212> PRT  
<213> Bacillus megaterium

<400> 7  
Met Asn Arg Glu Glu Phe Ser Gln Leu Met Gly Asn Val Leu Asn Met  
1 5 10 15  
Asn Leu Gln Tyr Gln Gln Ala Val Asn Glu Val Thr Gly Arg Tyr Leu  
20 25 30  
His Gln Val Asn Val Pro Thr Lys Glu Asp Val Ala Asn Val Ala Ser  
35 40 45  
Leu Val Ile Asn Val Glu Glu Lys Val Glu Leu Leu Glu Glu Gln Phe  
50 55 60  
Asp Asp Arg Phe Asp Glu Leu Glu Ala Gln Gln Glu Ser Ala Ser Ala  
65 70 75 80  
Leu Lys Lys Asp Val Thr Lys Leu Lys Ser Asp Val Lys Ser Leu Asp  
85 90 95  
Lys Lys Leu Asp Lys Val Leu Ser Leu Leu Glu Gly Gln Gln Lys Thr  
100 105 110  
Gln Asp Glu Leu Lys Glu Thr Ile Gln Lys Gln Ile Lys Thr Gln Gly  
115 120 125  
Glu Gln Leu Gln Ala Gln Leu Leu Glu Lys Gln Glu Lys Leu Ala Glu

-101 of 112-

Cannon Application

002070-04062460

130

135

140

Lys Pro Lys Ala Glu Ala Lys Ser Glu Ala Lys Pro Ser Asn Ala Gln  
145 150 155 160

Lys Thr Glu Gln Pro Ala Arg Lys  
165

<210> 8

<211> 741

<212> DNA

<213> Bacillus megaterium

<400> 8

atgacaacat tacaaggtaa agtagcaatc gtaacaggcg gatctaaagg tatcggggca 60  
gcaattacac gtgagcttgc ttctaattgga gtaaaagtag cagtaaacta taacagcagt 120  
aaagaatctg cagaagcaat tgtaaaagaa attaaagaca acggcggaga agctattgcg 180  
gttcaagctg acgtgtctta tgtagatcaa gcaaaacacc taatcgaaga aacaaaagct 240  
gcgtttggtc aattagacat tctagtaaac aatgctggaa ttacgcgcga ccgttcattc 300  
aagaagttag gtgaagaaga ttggaaaaaa gtaattgatg taaacttaca tagcgtatac 360  
aacacaacat cagctgcgct aacgcacctt ttagaatctg aagggtggctg tgttatcaat 420  
atttcatcaa ttattggtca agcgggcgga tttggtcaaa caaactactc agctgctaaa 480  
gcaggtatgc taggattcac taaatcatta gctcttgaac tagctaagac aggcgtaacg 540  
gttaatgcaa tttgcccagg atttattgaa acggaaatgg tgatggcaat tcctgaagat 600  
gttcgtgcaa aaattgttgc gaaaattcca actcgtcgct taggtcacgc tgaagaaatt 660  
gcacgtggag ttgtttactt agcaaaagac ggcgcgtaca ttacaggaca acagttaaac 720  
attaacggcg gcttatacat g 741

<210> 9

<211> 247

<212> PRT

<213> Bacillus megaterium

<400> 9

Met Thr Thr Leu Gln Gly Lys Val Ala Ile Val Thr Gly Gly Ser Lys  
1 5 10 15

Gly Ile Gly Ala Ala Ile Thr Arg Glu Leu Ala Ser Asn Gly Val Lys  
20 25 30

Val Ala Val Asn Tyr Asn Ser Ser Lys Glu Ser Ala Glu Ala Ile Val  
35 40 45

Lys Glu Ile Lys Asp Asn Gly Gly Glu Ala Ile Ala Val Gln Ala Asp  
50 55 60

Val Ser Tyr Val Asp Gln Ala Lys His Leu Ile Glu Glu Thr Lys Ala  
65 70 75 80

Ala Phe Gly Gln Leu Asp Ile Leu Val Asn Asn Ala Gly Ile Thr Arg  
85 90 95

-102 of 112-

Cannon Application

00479040-01000

Asp Arg Ser Phe Lys Lys Leu Gly Glu Glu Asp Trp Lys Lys Val Ile  
100 105 110

Asp Val Asn Leu His Ser Val Tyr Asn Thr Thr Ser Ala Ala Leu Thr  
115 120 125

His Leu Leu Glu Ser Glu Gly Gly Arg Val Ile Asn Ile Ser Ser Ile  
130 135 140

Ile Gly Gln Ala Gly Gly Phe Gly Gln Thr Asn Tyr Ser Ala Ala Lys  
145 150 155 160

Ala Gly Met Leu Gly Phe Thr Lys Ser Leu Ala Leu Glu Leu Ala Lys  
165 170 175

Thr Gly Val Thr Val Asn Ala Ile Cys Pro Gly Phe Ile Glu Thr Glu  
180 185 190

Met Val Met Ala Ile Pro Glu Asp Val Arg Ala Lys Ile Val Ala Lys  
195 200 205

Ile Pro Thr Arg Arg Leu Gly His Ala Glu Glu Ile Ala Arg Gly Val  
210 215 220

Val Tyr Leu Ala Lys Asp Gly Ala Tyr Ile Thr Gly Gln Gln Leu Asn  
225 230 235 240

Ile Asn Gly Gly Leu Tyr Met  
245

<210> 10  
<211> 1086  
<212> DNA  
<213> Bacillus megaterium

<400> 10  
gtggcaattc cttacgtgca agagtgggaa aaattaatca aatcaatgcc aagtgaatat 60  
aaaagtcttg caagacgttt taagcgtgca tatgaaatta tgacaacaga agcggaaaccg 120  
gaagttggat taacacccaaa agaggttatt tggaaaaaga acaaagcgaa attatatcgc 180  
tatacgccag taaaagataa cctgcataaa acaccaatct tactcgtata tgcattgatc 240  
aataaaccgt atatttttga tttaacacct ggaaacagcc ttgttgaata cttattaaac 300  
cgcggttttg acgtgtattt gcttgactgg ggaactcctg ggcttgaaga cagcaatatg 360  
aagctagatg attatatatt agattatatt ccaaaagcgg cgaaaaaggt gctgcgcact 420  
tctaaatctc ctgattttgtc tgttccttgg tactgcatgg gcggaactat gacatctatt 480  
tttgctgcat taaatgaaga cttgccgatt aaaaacttaa tttttatgac aagtccattt 540  
gatttttcgg atacagggtt atacggagca ttccatagatg atcgctactt taatttagat 600  
aaagcagtag atacattcgg aaacatccct ccagagatga ttgacttttg aaacaagatg 660  
ttaagccaa tcacgaattt ctacggcccg tatgtaacgt tgggtggaccg ttcggaaaat 720  
cagcggtttg ttgaaagctg gaagctaata caaaagtggg ttgctgacgg aatcccattt 780  
gctggcgaag cttatcgtca gtggattcgt gacttctatc aacaaaacaa actaatcaat 840  
ggtgaacttg aagttcgcgg acgcaaagta gatttaaaaa atattaaagc taatatttta 900

aacattgctg ctagccgtga tcatattgcg atgccgcac aagtggcagc tttaatggac 960  
gctgtttcaa gtgaagataa agagtataaa ttgttgcaaa caggtcacgt atctgttgta 1020  
tttgggtccaa aagcagtga ggaacatat ccttcaatcg gcgattggct agaaaaacgc 1080  
tctaaa 1086

<210> 11  
<211> 362  
<212> PRT  
<213> Bacillus megaterium

<400> 11  
Met Ala Ile Pro Tyr Val Gln Glu Trp Glu Lys Leu Ile Lys Ser Met  
1 5 10 15  
Pro Ser Glu Tyr Lys Ser Ser Ala Arg Arg Phe Lys Arg Ala Tyr Glu  
20 25 30  
Ile Met Thr Thr Glu Ala Glu Pro Glu Val Gly Leu Thr Pro Lys Glu  
35 40 45  
Val Ile Trp Lys Lys Asn Lys Ala Lys Leu Tyr Arg Tyr Thr Pro Val  
50 55 60  
Lys Asp Asn Leu His Lys Thr Pro Ile Leu Leu Val Tyr Ala Leu Ile  
65 70 75 80  
Asn Lys Pro Tyr Ile Leu Asp Leu Thr Pro Gly Asn Ser Leu Val Glu  
85 90 95  
Tyr Leu Leu Asn Arg Gly Phe Asp Val Tyr Leu Leu Asp Trp Gly Thr  
100 105 110  
Pro Gly Leu Glu Asp Ser Asn Met Lys Leu Asp Asp Tyr Ile Val Asp  
115 120 125  
Tyr Ile Pro Lys Ala Ala Lys Lys Val Leu Arg Thr Ser Lys Ser Pro  
130 135 140  
Asp Leu Ser Val Leu Gly Tyr Cys Met Gly Gly Thr Met Thr Ser Ile  
145 150 155 160  
Phe Ala Ala Leu Asn Glu Asp Leu Pro Ile Lys Asn Leu Ile Phe Met  
165 170 175  
Thr Ser Pro Phe Asp Phe Ser Asp Thr Gly Leu Tyr Gly Ala Phe Leu  
180 185 190  
Asp Asp Arg Tyr Phe Asn Leu Asp Lys Ala Val Asp Thr Phe Gly Asn  
195 200 205  
Ile Pro Pro Glu Met Ile Asp Phe Gly Asn Lys Met Leu Lys Pro Ile  
210 215 220

Thr Asn Phe Tyr Gly Pro Tyr Val Thr Leu Val Asp Arg Ser Glu Asn  
 225 230 235 240

Gln Arg Phe Val Glu Ser Trp Lys Leu Met Gln Lys Trp Val Ala Asp  
 245 250 255

Gly Ile Pro Phe Ala Gly Glu Ala Tyr Arg Gln Trp Ile Arg Asp Phe  
 260 265 270

Tyr Gln Gln Asn Lys Leu Ile Asn Gly Glu Leu Glu Val Arg Gly Arg  
 275 280 285

Lys Val Asp Leu Lys Asn Ile Lys Ala Asn Ile Leu Asn Ile Ala Ala  
 290 295 300

Ser Arg Asp His Ile Ala Met Pro His Gln Val Ala Ala Leu Met Asp  
 305 310 315 320

Ala Val Ser Ser Glu Asp Lys Glu Tyr Lys Leu Leu Gln Thr Gly His  
 325 330 335

Val Ser Val Val Phe Gly Pro Lys Ala Val Lys Glu Thr Tyr Pro Ser  
 340 345 350

Ile Gly Asp Trp Leu Glu Lys Arg Ser Lys  
 355 360

<210> 12  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:Synthetic

<400> 12  
 aayacrgtna aataynnnac rgtnatynnn gcdatgatg

39

<210> 13  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:Synthetic

<400> 13  
 gcdatyccdt aygtncarga agghttyaaa

30



Leu

<210> 20  
<211> 15  
<212> PRT  
<213> Bacillus megaterium

<400> 20  
Asn Thr Val Lys Tyr Xaa Thr Val Ile Xaa Ala Met Xaa Xaa Gln  
1 5 10 15

<210> 21  
<211> 11  
<212> PRT  
<213> Bacillus megaterium

<400> 21  
Ala Ile Pro Tyr Val Gln Glu Xaa Glu Lys Leu  
1 5 10

<210> 22  
<211> 813  
<212> DNA  
<213> Bacillus megaterium

<400> 22  
atggatgcat cacttttgtt agagtatgga tgggtattgc tagtgctggt tgcattagaa 60  
ggaatttttg cggcggataa tgctcttgtg atggctatta tgggtcaaaca tttaccggaa 120  
gaaaaacgca agaaggcatt attttacgga ttagccggtg cctttatatt tagatttggg 180  
tcgttgttct tgatttcatt ttttagtcgac gtatggcagc ttcaagctat aggagccatt 240  
tacttattgt tcatttccat taatcatatt gtgaagcgat atgtgaaaaa agacgatcat 300  
gaaaaagtga aagaagcaga cgagaaaaag ggctcagggt tctggatgac ggtttttaaaa 360  
gtagaaatag cagacattgc ttttgccgtt gattcaattt tggccgctgt ggctctcgcc 420  
gttacgttgc caacaacaaa tcttcctcaa attggcggac tcgacggcgg acaattcttg 480  
gtgatcttcg ccggaggaat tatgggatta attattatgc gttttgctgc aacttggttc 540  
gtcaagctat taaatacgcg cccaggccta gaaacggcgg cttttgctat tgtaggctgg 600  
gtaggagtta agttagcggc ctataccctt gctcatccag agttaggtat tattaatgaa 660  
catttccctg aatcaaaagt gtggaaaatt acgttttggg ttgtgttact tggcatagct 720  
gcttcaggct ggtttctatc taaaaataaa gaacaaactg atcttgaagg ctgagagaaa 780  
gaaaaagaat cgtaaaaaaa aattgaaaat caa 813

<210> 23  
<211> 271  
<212> PRT  
<213> Bacillus megaterium

<400> 23

002070"04062460

Met Asp Ala Ser Leu Leu Leu Glu Tyr Gly Trp Val Leu Leu Val Leu  
1 5 10 15  
Val Ala Leu Glu Gly Ile Leu Ala Ala Asp Asn Ala Leu Val Met Ala  
20 25 30  
Ile Met Val Lys His Leu Pro Glu Glu Lys Arg Lys Lys Ala Leu Phe  
35 40 45  
Tyr Gly Leu Ala Gly Ala Phe Ile Phe Arg Phe Gly Ser Leu Phe Leu  
50 55 60  
Ile Ser Phe Leu Val Asp Val Trp Gln Leu Gln Ala Ile Gly Ala Ile  
65 70 75 80  
Tyr Leu Leu Phe Ile Ser Ile Asn His Ile Val Lys Arg Tyr Val Lys  
85 90 95  
Lys Asp Asp His Glu Lys Val Lys Glu Ala Asp Glu Lys Lys Gly Ser  
100 105 110  
Gly Phe Trp Met Thr Val Leu Lys Val Glu Ile Ala Asp Ile Ala Phe  
115 120 125  
Ala Val Asp Ser Ile Leu Ala Ala Val Ala Leu Ala Val Thr Leu Pro  
130 135 140  
Thr Thr Asn Leu Pro Gln Ile Gly Gly Leu Asp Gly Gly Gln Phe Leu  
145 150 155 160  
Val Ile Phe Ala Gly Gly Ile Met Gly Leu Ile Ile Met Arg Phe Ala  
165 170 175  
Ala Thr Trp Phe Val Lys Leu Leu Asn Thr Arg Pro Gly Leu Glu Thr  
180 185 190  
Ala Ala Phe Ala Ile Val Gly Trp Val Gly Val Lys Leu Ala Val Tyr  
195 200 205  
Thr Leu Ala His Pro Glu Leu Gly Ile Ile Asn Glu His Phe Pro Glu  
210 215 220  
Ser Lys Val Trp Lys Ile Thr Phe Trp Ile Val Leu Leu Gly Ile Ala  
225 230 235 240  
Ala Ser Gly Trp Phe Leu Ser Lys Asn Lys Glu Gln Thr Asp Leu Glu  
245 250 255  
Gly Ser Glu Lys Glu Lys Glu Ser Leu Lys Lys Ile Glu Asn Gln  
260 265 270

<210> 24

100-443886-100

atgtcacaa	aagttcaaac	gcttcacatcg	cttgaaacgc	ttgtactgac	gattcagcaa	60
ggggataaac	aattacataa	tgaaatgatt	caacaatata	aaccgtttat	tgctaaagtt	120
gtttcagctg	tatgtaaacg	ttatataagt	gaagctgacg	atgaatttag	cattgggtctg	180
attgcattta	atgaagccat	tgaaaattac	acaatccaaa	aaggacgatac	tcttcttgca	240
tttgcggaac	ttattattaa	aagaagagta	atcgactata	ttcgaaaaga	aaagcgaaat	300
caaacgctgc	tctataaccg	aattgaaaat	gaaggtttta	ttcaaggtaa	ggtagaaagg	360
gatatatcgc	tttctaacta	taaaaggcaa	agtgaaactt	catatatattca	agaggaaatg	420
acttattttt	gtcaggcgct	aaaattgttt	aaattaactc	ttgaagacat	tattaacacg	480
tctcctaaac	ataaggatgc	aaggggaaat	gcagtggaag	ttgcatcttt	tatcgtcaat	540
gaaaaagaat	taaaagataa	gctgttttta	aagcggcagc	ttcctattcg	cttgattgaa	600
aaacatgtca	aagtaagcgg	gaaaacaatt	gaaagaaacc	gtaaatatat	tatcgcgatg	660
gttattatat	taqcqqqqga	ctacgtgtat	ttaaaagact	atattatg		708

<400> 25																
Met	Leu	Thr	Lys	Val	Gln	Thr	Pro	Pro	Ser	Leu	Glu	Thr	Leu	Val	Leu	
1				5					10					15		
Thr	Ile	Gln	Gln	Gly	Asp	Lys	Gln	Leu	His	Asn	Glu	Met	Ile	Gln	Gln	
			20					25					30			
Tyr	Lys	Pro	Phe	Ile	Ala	Lys	Val	Val	Ser	Ala	Val	Cys	Lys	Arg	Tyr	
		35					40					45				
Ile	Ser	Glu	Ala	Asp	Asp	Glu	Phe	Ser	Ile	Gly	Leu	Ile	Ala	Phe	Asn	
	50					55					60					
Glu	Ala	Ile	Glu	Asn	Tyr	Thr	Ile	Gln	Lys	Gly	Arg	Ser	Leu	Leu	Ala	
65					70					75					80	
Phe	Ala	Glu	Leu	Ile	Ile	Lys	Arg	Arg	Val	Ile	Asp	Tyr	Ile	Arg	Lys	
				85					90					95		
Glu	Lys	Arg	Asn	Gln	Thr	Leu	Leu	Tyr	Asn	Arg	Ile	Glu	Asn	Glu	Gly	
			100					105					110			
Phe	Ile	Gln	Gly	Lys	Val	Glu	Arg	Asp	Ile	Ser	Leu	Ser	Asn	Tyr	Lys	
		115					120					125				
Arg	Gln	Ser	Glu	Thr	Ser	Tyr	Ile	Gln	Glu	Glu	Met	Thr	Tyr	Phe	Cys	
	130					135					140					
Gln	Ala	Leu	Lys	Leu	Phe	Lys	Leu	Thr	Leu	Glu	Asp	Ile	Ile	Asn	Thr	

002070"04052450

145                      150                      155                      160  
Ser Pro Lys His Lys Asp Ala Arg Gly Asn Ala Val Glu Val Ala Ser  
                         165                      170                      175  
Phe Ile Val Asn Glu Lys Glu Leu Lys Asp Lys Leu Phe Leu Lys Arg  
                         180                      185                      190  
Gln Leu Pro Ile Arg Leu Ile Glu Lys His Val Lys Val Ser Arg Lys  
                         195                      200                      205  
Thr Ile Glu Arg Asn Arg Lys Tyr Ile Ile Ala Met Val Ile Ile Leu  
                         210                      215                      220  
Ala Gly Asp Tyr Val Tyr Leu Lys Asp Tyr Ile Met  
225                      230                      235

<210> 26  
<211> 957  
<212> DNA  
<213> Bacillus megaterium

<400> 26  
atgccacaac catggaaacg acgagtaagg cagatgtctt cagctcaaatt tattgttaca 60  
ttttacatag tggtctgttac gcttgggttt ctattactta gtattccaga agctttaagg 120  
ccaggagcaa agttagcatt tattgatcgc ttatttattg ccgttagtgc ggtaagtgtg 180  
acagggtctga cacctgtctc gactccagat acatttagta caacgggcta ttttttactc 240  
gtttttatatt ttcaaactcg tggtatttgt gtaatgacac tcagtacatt tatttggatg 300  
atttttaggta aaaaaactcg tctgaaggaa cgtcagctca ttatgacgga ccataatcaa 360  
tcccgtttat caggattagt tgatttgatg agaaatattt tatttattat ttttgccatt 420  
gaactagttg gcgccattat tttagggtta cattttctcc gttattattc gagctggaca 480  
gatgcgtttt tgcattggtt ctttgcttct gtcagtgcga caacaaatgc tggcttcgat 540  
attacaggat cttcatttat tccgtatgcc catgattatt tegtacaagt ggtaaccgtt 600  
attttaatta cgcttggagc gattggattc cctgtattaa ttgaaatcaa gcactatttt 660  
ttaacattta aagataagcg taaatttcaa ttttcgctat ttacgaagct aacgactatt 720  
atgttttttc tgctgttagg agggggaaca atcttgattc ttgtgctaga gcattcagga 780  
tttctagcag ataagtcttg ggatgaatcg tttttttatg cgtttttcca atccgctgcc 840  
acaaggagcg gaggagtggc gaccatgaat attaataagt tttcacttc tacgttaatt 900  
atgatgagcg cgatgatgtt tatcgggtgt tcaccgagtt cagtaggggg aggaatt 957

<210> 27  
<211> 319  
<212> PRT  
<213> Bacillus megaterium

<400> 27  
Met Pro Gln Pro Trp Lys Arg Arg Val Arg Gln Met Ser Ser Ala Gln  
1                      5                      10                      15  
Ile Ile Val Thr Phe Tyr Ile Val Ala Val Thr Leu Gly Phe Leu Leu  
20                      25                      30



305

310

315

<210> 28

<211> 195

<212> DNA

<213> Bacillus megaterium

<400> 28

atggctagaa caaataaaact attaacacca ggagtagaac aattttttaga tcaatataaa 60  
tatgaaatcg ctcaagaatt tggggtaact ctaggttctg aactgctgc acgcagcaac 120  
ggttcagtag gcggagaaat cacaaaacgc ttggtgcaac aagctcaagc tcaacttaagc 180  
ggcagcacac aaaaa 195

<210> 29

<211> 65

<212> PRT

<213> Bacillus megaterium

<400> 29

Met Ala Arg Thr Asn Lys Leu Leu Thr Pro Gly Val Glu Gln Phe Leu  
1 5 10 15

Asp Gln Tyr Lys Tyr Glu Ile Ala Gln Glu Phe Gly Val Thr Leu Gly  
20 25 30

Ser Asp Thr Ala Ala Arg Ser Asn Gly Ser Val Gly Gly Glu Ile Thr  
35 40 45

Lys Arg Leu Val Gln Gln Ala Gln Ala His Leu Ser Gly Ser Thr Gln  
50 55 60

Lys

65